WO2022098372A1 - Vaccins anti-gucy2c et vaccination - Google Patents

Vaccins anti-gucy2c et vaccination Download PDF

Info

Publication number
WO2022098372A1
WO2022098372A1 PCT/US2020/059752 US2020059752W WO2022098372A1 WO 2022098372 A1 WO2022098372 A1 WO 2022098372A1 US 2020059752 W US2020059752 W US 2020059752W WO 2022098372 A1 WO2022098372 A1 WO 2022098372A1
Authority
WO
WIPO (PCT)
Prior art keywords
gucy2c
cancer
gcc
seq
nucleic acid
Prior art date
Application number
PCT/US2020/059752
Other languages
English (en)
Inventor
Adam E. Snook
Scott A Waldman
Trevor R. BAYBUTT
John C. FLICKINGER
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Priority to JP2022526700A priority Critical patent/JP2023548255A/ja
Priority to KR1020227019215A priority patent/KR20230026980A/ko
Priority to EP20960974.2A priority patent/EP4055176A4/fr
Priority to AU2020475819A priority patent/AU2020475819A1/en
Priority to CA3158649A priority patent/CA3158649A1/en
Publication of WO2022098372A1 publication Critical patent/WO2022098372A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01002—Guanylate cyclase (4.6.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Definitions

  • Improvements in screening provide the opportunity to identify many individuals who have early stage cancer as well as many who do not have cancer but who are genetically predisposed to developing cancer and thus at an elevated risk of developing cancer.
  • improvements in treatment there are numerous people who have either had cancer removed or in remission. Such people are at a risk of relapse or recurrence and so are also at an elevated risk of developing cancer.
  • compositions useful to treat individuals suffering GUCY2C expressing tumors/cancers There is a need for compositions useful to treat individuals suffering from GUCY2C expressing cancers. There is a need for improved methods of preventing a recurrence of GUCY2C expressing cancers in individuals who have been treated for such cancers. There is a need for compositions useful to prevent a recurrence of GUCY2C expressing cancers in individuals who have been treated for such cancers. There is a need for improved methods of preventing GUCY2C expressing cancers in individuals, particularly those who have been identified as having a genetic predisposition for such cancers. There is a need for compositions useful for preventing GUCY2C expressing cancers in individuals. There is a need for improved methods of identifying compositions useful to treat and prevent GUCY2C expressing cancers in individuals.
  • Figure 1 shows the alignment of Ad5.F35-hGCC-PADRE and Wild Type Ad5.
  • Ad5.F35-hGCC-PADRE differs from that of Ad5 by 1) replacement of the El region (E1A and E1B) with the hGCC-PADRE expression cassette, 2) deletion of most of the E3 region and 3) replacement of the Ad5 fiber with the Ad35 fiber.
  • Figure 2 shows Ad5F35-hGUCY2C-PADRE map.
  • FIG. 3 panels A-E refer to Ad5 neutralizing Abs limit GUCY2C responses in humans.
  • Patient serum samples collected prior to vaccination (day 0) where analyzed for Ad5 neutralizing antibodies (NAbs) employing an in vitro Ad5-GFP reporter virus inhibition assay (A).
  • the Ad5 NAb titer was calculated as the dilution of serum that produced 50% inhibition of GFP reporter expression.
  • B Patients were rank-ordered by Ad5 NAb titers and patients with titers ⁇ 200 where designated as Ad5 NAb Low, while those with titers >200 where designated Ab5 NAb High (dotted line indicates a titer of 200).
  • C-E Antigen-specific responses to GUCY2C (C), PADRE (D), and Ad5 (E) were compared in Ad5 NAb Low and High patient populations by IFN ⁇ -ELISpot.
  • FIG. 4 panels A-D refer to Ad5 neutralizing antibodies limit GUCY2C responses in mice.
  • NAb Ad5 neutralizing antibody
  • B two weeks after preconditioning, serum was collected and Ad5 NAb titers (B) were determined using an in vitro assay to quantify inhibition of A549 cell infection by an Ad5-GFP reporter virus in the presence of serum titrations (A).
  • the Ad5 NAb titer was calculated as the dilution of serum that produced 50% inhibition of GFP reporter expression.
  • mice were then immunized with 108 IFU of Ad5-mGUCY2C-S1 expressing mouse GUCY2C fused to the CD4 + T-helper cell epitope S1.
  • GUCY2C-specific antibody (C) and CD8 + T-cell responses (D) were quantified two weeks later by ELISA and IFN ⁇ -ELISpot, respectively.
  • NS not significant, * P ⁇ 0.05, *** P ⁇ 0.001, **** P ⁇ 0.0001 Two-way ANOVA.
  • Figure 5 refers to Ad5 and Ad5.F35 NAb Titers in Phase 1 Subjects.
  • Pre- vaccination serum samples from the Phase 1 study subjects were tested for Ad5 or Ad5.F35 neutralizing antibody (NAb) titers using an Ad5-GFP or Ad5.F35-GFP reporter virus inhibition bioassay. Titers were calculated as the dilution of serum producing 50% inhibition by non-linear regression. Values indicate the computed titers and standard deviation for each subject.
  • the dashed line indicates a titer of 200, the standard threshold for “high” neutralizing titers. All subjects possessed less neutralizing immunity for Ad5.F35 than Ad5. Importantly, while 5/10 subjects possessed “high” Ad5 NAb titers, only 1 subject possessed “high” Ad5.F35 NAb titers.
  • FIG. 6 panels A-D Construction of Ad5.F35-GUCY2C-S1 and antigen expression.
  • A Reported international seroprevalence of Ad5 and Ad35.12
  • B The L5 gene encoding the fiber protein from Ad5 was replaced with the L5 gene from Ad35, producing the chimeric adenoviral vector Ad5.F35.
  • Recombinant Ad5.F35-GUCY2C-S1 was produced by inserting mouse GUCY2C-S1 into the El region of E1/E3 deleted Ad5.F35.
  • C and D The human alveolar basal epithelial cell line, A549, was transduced in duplicate with Ad5.F35-GUCY2C-S1 at a multiplicity of infection (MOI) from 0 to 10,000 for 48 hours (C) or at an MOI of 10,000 for 0, 24, 48, and 72 hours (D).
  • MOI multiplicity of infection
  • Supernatants from infected cells were analyzed for GUCY2C-S1 protein expression by immunoblot. Protein expression was quantified by densitometry and plotted relative to uninfected cells. Error bars indicate mean+SEM.
  • FIG. 7 panels A-D Construction of Ad5.F35-GUCY2C-S1 and antigen expression.
  • A Reported international seroprevalence of Ad5 and Ad35.12
  • B The L5 gene encoding the fiber protein from Ad5 was replaced with the L5 gene from Ad35, producing the chimeric adenoviral vector Ad5.F35.
  • Recombinant Ad5.F35-GUCY2C-S1 was produced by inserting mouse GUCY2C-S1 into the El region of E1/E3 deleted Ad5.F35.
  • C and D The human alveolar basal epithelial cell line, A549, was transduced in duplicate with Ad5.F35-GUCY2C-S1 at a multiplicity of infection (MOI) from 0 to 10,000 for 48 hours (C) or at an MOI of 10,000 for 0, 24, 48, and 72 hours (D).
  • MOI multiplicity of infection
  • Supernatants from infected cells were analyzed for GUCY2C-S1 protein expression by immunoblot. Protein expression was quantified by densitometry and plotted relative to uninfected cells. Error bars indicate mean+SEM.
  • FIG 8 panels A-D Antitumor efficacy of Ad5-GUCY2C-S1 and Ad5.F35- GUCY2C-S1.
  • Tumor burden (B) was analyzed by one-way analysis of variance and survival comparisons (D) were analyzed by the Mantel-Cox log-rank test.
  • asterisks (*) indicate comparisons of GUCY2C vaccines to the control and brackets (]) indicate comparisons between Ad5 and Ad5.F35 vaccines, ns, not significant; Ad5, adenovirus serotype 5.
  • Ad5.F35 resists neutralization associated with pre-existing anti-Ad5 immunity in mice and humans.
  • FIG 10 panels A-G Safety and immunogenicity of multiple Ad5.F35- GUCY2C-S1 administrations.
  • mice were euthanized to quantify organ pathology by weight, biodistribution by quantitative PCR, and GUCY2C-specific CD8+ T-cell responses by interferon gamma (IFN- ⁇ ) ELISpot (E-G).
  • IFN- ⁇ interferon gamma
  • E-G ELISpot
  • FIG. 11 Recombinant Lm-GUCY2C secretes GUCY2C inside infected J774.A1 macrophages.
  • J774A.1 cells were plated into a 6 well plate and allowed to form monolayers. Macrophages were than infected with 4x10 7 CFU of control Lm or Lm- GUCY2C and incubated at 37° C for one hour. One hour post- infection, media was aspirated, cells washed lx with PBS and fresh media containing 10ug/mL gentamicin was added to remove extracellular Lm. Infected macrophages were incubated for 7 additional hours at 37°C.
  • Lysates from infected cells were then prepared and stained using antibodies against GUCY2C or the Lm antigen p60.
  • Lane 1 uninfected J774A.1 cells.
  • Lanes 2 J77A.1 infected with control Lm.
  • Lane 3 J774A.1 infected with Lm-ActA-GUCY2C.
  • Lane 4 J774A.1 infected with Lm-ActA-Synl8x5-GUCY2C.
  • FIG. 12 Recombinant Lm-GUCY2C enhances GUCY2C-specific CD8+ T cell responses following Ad5-GUCY2C-S1 vaccination.
  • BALB/c mice were immunized intramuscularly with 1x108 plaque forming units (PFU) of Ad5-GUCY2C-S1 on day 0.
  • PFU plaque forming units
  • mice were immunized with 1x107 colony forming units (CFU) of control Lm or recombinant Lm expressing GUCY2C [Lm-ActA-Syn18x5-GUCY2C (“Lm- GUCY2C”)].
  • GUCY2C-specific T cells were quantified by IFN ⁇ ELISpot, with DMSO serving as a negative control.
  • FIG. 14 1st Generation Lm-GCC Vaccines. Three vaccines were generated: control Lm containing only the transfer plasmid without GCC; LLO-GCC fusion protein; and LLO-GCC-S1 fusion protein.
  • FIG. 15 1st Generation Lm Vaccine Quality Control. Listeria cultures were grown at 37°C. At OD600 > 0.5, cultures were centrifuged at 4,000xG for 10 minutes and supernatants were collected. Proteins were precipitated from supernatant using trichloroacetic acid. Protein (30 ⁇ g) was loaded in each lane of a 4-12% Bis-Tris Gel. Gels were stained with GCC monoclonal antibody (clone MS 20) or polyclonal anti-LLO. Predicted weight of both LLO-GCC and LLOGCC-S1 fusion proteins is estimated ⁇ 89 kDa.
  • FIG. 16 1st Generation Lm Vaccine Immunogenicity.
  • Control Lm-LLO
  • Lm- LLO-GCC Lm- LLO-GCC
  • Lm-LLO-GCC-S1 vaccines were administered to wild-type BALB/c mice at 107 CFU/mouse.
  • Ad5- GCC-S1 was administered at 109 IFU as a positive control.
  • GCC-specific CD8+ T-cell responses were measured by IFN ⁇ -ELISpot. No responses were detected against GCC in the control, LmLLO-GCC, or Lm-LLO-GCC-S1- immunized mice but were readily detected in Ad5-GCC-S1- immunized mice (left).
  • Lm and Ad5 vaccines induced strong vector- specific T-cell responses directed against LLO or DBP, respectively (right), confirming adequate Lm- LLO-GCC vaccine exposure and immunogenicity.
  • FIG. 1st generation vaccines employed the full extracellular domain of GCC (residues 23-429), 2nd generation designs employed shorter fragments of GCC. Each fragment contained approximately 1/3 of GCC with discrete CD4+ and CD8+ epitope profiles indicated below each construct.
  • FIG. 1 2nd Generation Lm Vaccine Quality Control.
  • Listeria cultures were grown at 37°C. When OD600 > 0.5, cultures were centrifuged at 4,000xG for 10 minutes and supernatants were collected. Proteins were precipitated from supernatant using trichloroacetic acid. Protein (30 ⁇ g) was loaded in each lane of a 4-12% Bis-Tris Gel. Gels were stained with GCC monoclonal antibodies MS7, MS20, MS24 and detected with HRP-conjugated goat anti-mouse secondary antibody and luminescent substrate.
  • FIG 19 panels A and B. 2nd Generation Vaccine Immunogenicity.
  • 2nd generation Lm-LLO-GCC vaccines containing GCC fragments were administered to Gcc- /- (A) or Gcc+/+ (B) mice.
  • Gcc-/- mice produced robust CD4 + T-cell responses against GCC when immunized with the CD4 + T-cell epitope-containing fragments 1 and 2 (A).
  • Gcc+/+ mice failed to produce GCC-specific CD8 + T-cell responses when immunized with the CD8 + T-cell epitope-containing fragments 2 and 3 (B)
  • FIG. 20 panels A, B and C. Lm-LLO-GCC Antitumor Immunity.
  • FIG 21 panels A, B, C and D. Lm-ActA-GCC Vaccines.
  • vaccine “B” contains a synthetic sequence (Synl8) to enhance Acta-GCC fusion protein production.
  • Synl8 significantly improves Acta-GCC production in macrophages infected with the various Lm vaccines in vitro.
  • Anti-P60 detects an Lm protein, allowing for normalization of GCC expression levels in Lm- infected macrophages.
  • Wild-type BALB/c mice were immunized with vaccine “A” (C) or “B” (D) or positive control Ad5-GCC-S1 and GCC-specific CD8 + T-cell responses were measured by IFN ⁇ -ELISpot. No responses were detected in the Lm-immunized groups. In C and D, individual mice are shown for vaccines “A” and “B”.
  • FIG. 22 Lm-ActA-GCC Multi-Epitope Vaccine. Recombinant Lm was produced containing ActA fused to 5 copies of the dominant GCC CD8 + T-cell epitope in tandem (vaccine “C”), however, immunization of mice with this vaccine produced no GCC- specific CD8 + T-cell response. Individual mice are shown for vaccine “C”.
  • FIG. 23 Lm- Act A- Multi-Epitope Vaccine.
  • Recombinant Lm was produced containing ActA fused to 4 tandem epitopes corresponding to the dominant CD8 + T-cell epitopes from E. coli ⁇ -galactosidase (LacZ), GCC, the mouse homolog of Her2, and Ad5 (vaccine “D”). Wild-type BALB/c mice were immunized, and responses were quantified by IFN ⁇ -ELISpot.
  • FIG. 24 panels A-C: Construction of Lm-GUCY2C.
  • GUCY2C ⁇ usion protein was detected by (B) western blot and (C) immunofluorescence.
  • FIG. 25 panels A-D Heterologous Ad5.F35-GUCY2C-S1 + Lm-GUCY2C immunization enhances GUCY2C-specific CD8 + T cell responses and antitumor immunity.
  • Adenovirus vaccines were administered intramuscularly (i.m.) as 10 10 vp of Ad5.F35-GUCY2C-S1 or control Ad5.F35 and Lm vaccines were administered intravenously(i.v.) as 5x10 6 CFU of Lm-GUCY2C or control Lm.
  • mice were harvested and GUCY2C-specific CD8 + T cells quantified by IFN- ⁇ ELISpot (A) or challenged i.v. with 5x 10 5 CT26 colorectal cancer cells expressing GUCY2C and firefly luciferase.
  • mice were injected with D-luciferin substrate and imaged (B).
  • FIG. 26 panels A-C Pre-existing Ad5 immunity does not impact Ad5.F35- GUCY2C-S1 + Lm-GUCY2C immunization.
  • mice from each group were sacrificed to evaluate GUCY2C-speicfic CD8 + T cell responses (C) and the remaining ten mice were challenged with 5x10 5 CT26 colorectal cancer cells expressing GUCY2C and firefly luciferase.
  • FIG. 27 panels A-E Prime-boost enhances the avidity and polyfunctionality of the GUCY2C-specific CD8+ T cell pool
  • Ad5.F35-GUCY2C-S1 primarye
  • Ad5.F35-GUCY2C-S1 + Lm-GUCY2C(prime-boost) vaccination regimens At the peak effector response, 14 days following prime and 6 days following prime-boost vaccination, splenocytes were collected with GUCY2C-specific CD8+ T cell avidity (A) quantified by IFN- ⁇ ELISpot and polyftmctionality quantified by flow cytometry (B-E).
  • FIG. 28 panels A-D Heterologous prime-boost immunization does not induce toxicity.
  • B-D Survival and weights were monitored throughout the experiment.
  • SEQ ID NO: 1 DNA sequence of Human GUCY2C (Genbank accession number BC136544), incorporated herein by reference.
  • SEQ ID NO:2 Predicted Amino Acid Sequence of Human GUCY2C.
  • SEQUENCE ID NOG Codon optimized DNA sequence of Human GUCY2C.
  • SEQUENCE ID NO:4 Predicted Amino Acid Sequence of Human GUCY2C.
  • SEQ ID NOG Codon optimized DNA sequence of soluble human GUCY2C.
  • SEQ ID NO 6 Soluble human GUCY2C predicted amino acid sequence.
  • SEQ ID NO: 7 DNA sequence encoding a PADRE.
  • SEQ ID NO: 8 Predicted amino acid sequence of the PADRE of SEQ NO: 6.
  • SEQ ID NO:9 Codon optimized DNA sequence of a soluble human GUCY2C fused in frame with DNA sequence encoding a PADRE (C terminal fusion).
  • SEQ ID NO: 10 Predicted amino acid sequence of codon optimized DNA sequence of a soluble human GUCY2C fused in frame with DNA sequence encoding a PADRE (N terminal fusion).
  • SEQ ID NO. 11 Ad5.F35-hGUCY2C-PADRE vector sequence.
  • SEQ ID NO: 12 T cell epitope present in the 33 kDa C-terminal region of P. vivax MSP1.
  • SEQ ID NO:13 T cell epitope present in circumsporozoite protein of Plasmodium falciparum.
  • SEQ ID NO: 14 T cell epitope present in circumsporozoite protein of Plasmodium falciparum.
  • SEQ ID NO:15 T cell epitope present in circumsporozoite protein of Plasmodium falciparum.
  • SEQ ID NO: 16 T cell epitope present in circumsporozoite protein of Plasmodium falciparum.
  • SEQ ID NO: 17 T cell epitope present in circumsporozoite protein of Plasmodium falciparum.
  • SEQ ID NO:18 T cell epitope present in circumsporozoite protein of Plasmodium falciparum.
  • SEQ ID NO: 19 T cell epitope tetanus toxoid TT830-844.
  • SEQ ID NO:20 T cell epitope tetanus toxoid TT947-967.
  • SEQ ID NO:21 T cell epitope tetanus toxoid TT590-603.
  • SEQ ID NO:22 T cell epitope tetanus toxoid TT615-629.
  • SEQ ID NO:23 T cell epitope tetanus toxoid TT639-652.
  • SEQ ID NO:24 T cell epitope tetanus toxoid TT830-843.
  • SEQ ID NO:25 T cell epitope tetanus toxoid TT947-967.
  • SEQ ID NO:26 T cell epitope influenza hemagglutinin residues 306-318.
  • SEQ ID NO:27 T cell epitope enterovirus 71 VP1 capsid protein residues 66-77.
  • SEQ ID NO:28 T cell epitope enterovirus 71 VP1 capsid protein residues 145-
  • SEQ ID NO:29 T cell epitope enterovirus 71 VP1 capsid protein residues 247-261
  • SEQ ID NO:31 T cell epitope HIV Gagi3i-i5.
  • SEQ ID NO:32 T cell epitope HIV Gag 211-230.
  • SEQ ID NO:33 T cell epitope HIV Gag 241-260.
  • SEQ ID NO:34 T cell epitope HIV Gag 263-277.
  • SEQ ID NO:35 T cell epitope HIV Gag 271-290.
  • SEQ ID NO:36 T cell epitope HIV Gag 291-310.
  • SEQ ID NO:37 T cell epitope HIV Gag 301-320.
  • SEQ ID NO:38 T cell epitope HIV Gag 321-340.
  • SEQ ID NO:39 T cell epitope HIV Gag 331-350.
  • SEQ ID NO:40 T cell epitope Ad5 hexon protein residues 556 to 580.
  • SEQ ID NO:41 T cell epitope Ad5 hexon protein residues 56-80.
  • SEQ ID NO:42 T cell epitope Ad5 hexon protein residues 316-335.
  • SEQ ID NO:43 T cell epitope Ad5 hexon protein residues 906-930. DETAILED DESCRIPTION OF THE INVENTION
  • GUIC2 As used herein, “GUCYC2”, “GCC”, ‘human GUCYC2”, “human GCC”, “GUCYC2 protein”, “GCC protein”, “human GUCYC2 protein” and “human GCC protein” are used interchangeably herein to refer to human guanylyl cyclase C protein.
  • a nucleic acid sequence that encodes human GUCYC2 is set forth in SEQ ID NO:1 (Genbank accession number BC136544).
  • the human GUCYC2 protein encoded by the longest open reading frame of SEQ ID NO: 1 has the amino acid sequence set forth at SEQ ID NO:2 (Genbank accession number AAB 19934).
  • a codon optimized sequence that encodes human GUCYC2 has been described by Magee et. al. (Magee MS et al. (2016) Cancer Immunol Res 6:509-516, which is incorporated herein by reference) and is set forth at SEQ ID NO: 3.
  • the GUCYC2 protein is a cell-surface or membrane-bound receptor protein.
  • the GUCYC2 protein has some generally accepted domains, each of which contributes a separable function to the GUCYC2 molecule. These domains include a signal sequence (also referred to interchangeably as a signal peptide), an extracellular domain, a transmembrane domain, a kinase homology domain and a guanylyl cyclase catalytic domain (the kinase homology domain and the guanylyl cyclase catalytic domain together are sometimes referred to interchangeably as an intracellular or cytoplasmic domain).
  • the domains are described herein from the N-terminus to the C-terminus as they occur when the protein is produced in the cell.
  • the GUCYC2 signal sequence is present the newly synthesized GUCYC2 protein at the N-terminus.
  • the GUCYC2 signal sequence functions in the translocation of the protein from location where it is initially produced in the cell.
  • the GUCYC2 signal peptide is typically excised for maturation to yield functional mature protein as part of or following protein transport.
  • the GUCYC2 extracellular domain is the portion of the GUCYC2 protein that is exposed externally on the outside of the cell.
  • the GUCYC2 extracellular domain includes a GUCYC2 the portion of the GUCYC2 protein that bind to the GUCYC2 protein’s naturally occurring agonist ligands, guanylin and uroguanylin, as well as naturally occurring and synthetic agonist and antagonist ligands such as, for example, the E. coli heat stable enterotoxin ST.
  • the GUCYC2 extracellular domain includes all amino acid residues of the sequence between the GUCYC2 signal sequence and the GUCYC2 transmembrane domain. That is, the GUCYC2 extracellular domain includes all amino acid residues from the first residue after the GUCYC2 signal sequence to the last residue before the GUCYC2 transmembrane domain.
  • the transmembrane domain is positioned within and spans the cell membrane.
  • the transmembrane domain anchors the GCC protein in the cell membrane.
  • the kinase homology domain and guanylyl cyclase catalytic domain are positioned in the interior of the cell and function to relay the signal when the receptor is activated by its binding to an agonist ligand.
  • the kinase homology domain is predicted to have tyrosine kinase activity; the guanylyl cyclase catalytic domain is predicted to have guanylyl cyclase activity.
  • Ad5.Fib35 adenoviral vector and a “Ad5.F35 adenoviral vector” are used interchangeably and refer to an adenoviral vector in which the DNA encoding the native Ad5 fiber or shaft and knob portion of the fiber has been replaced by those derived from serotype B adenovirus Ad35.
  • a “replication defective adenoviral vector” means an adenoviral vector deficient in one or more regions of the adenoviral genome that are essential to viral replication (e.g., El, E2 or E4 or combination thereof), and thus unable to propagate in the absence of trans-complementation (e.g., provided by either complementing cells or a helper virus).
  • replication defective adenoviral vector is minimal (or gutless) adenoviral vector which lacks all functional genes including early (El, E2, E3 and E4) and late genes (LI, L2, L3, L4 and L5) with the exception of cis-acting sequences (see for example Kovesdi et al., Current Opinion in Biotechnology 8 (1997), 583-589; Yeh and Perricaudet, FASEB 11 (1997), 615-623; WO 94/12649; WO 94/28152).
  • the replication-deficient adenoviral vector may be readily engineered by one skilled in the art, taking into consideration the required minimum sequences, and is not limited to these exemplary embodiments.
  • Gene expression cassette means a DNA construct that is or can be inserted into an adenoviral backbone capable of driving expression of soluble GUCYC2 or a soluble GUCYC2 fused in frame to a universal CD4+ epitope.
  • Gene expression cassettes generally are constructed to express one or more foreign antigens-of- interest under the control of a given promoter and may include a polyadenylation signal such as for example the BGH polyadenylation signal or those derived from SV40, and/or other elements, such as a Kozak region and/or additional termination signals not already provided by the host vector or the coding region to be expressed.
  • the CMV IE promoter is commonly used in a gene expression cassette because it is efficiently expressed in many tissue types.
  • Other promoters might be used in gene expression cassette including, for example, simian virus 40 (SV40) early promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, the human hemoglobin promoter, a dendritic cell specific such as promoter CDllc (Masood, R, et al, 2001 Int J Mol Med 8: 335-343, Somia, N.V, et al, 1995 Proc Acad Sci USA 92: 7570-7574, which are incorporated herein by reference) as well as muscle specific promoters including the myosin promoter, the muscle creatinine kinase (MCK) promoter, the desmin promoter and the mammalian troponin 1 promoter.
  • SV40 simian virus 40
  • MCK muscle creatinine kinase
  • soluble GUCYC2 As used herein the term “soluble GUCYC2”, “soluble GCC”, “soluble human GUCYC2”, “soluble human GCC”, “soluble GUCYC2 domain”, “soluble GCC domain”, “soluble human GUCYC2 domain” and “soluble human GCC domain” are used interchangeably and refer to a fragment of human GUCY2C that comprises a GUCY2C extracellular domain or a fragment thereof comprising a sequence from human GUCY2C that is at least 330-423 amino acid residues including the sequence from amino acid residue 54 to amino acid residue 384 of the functional mature GCC protein, and optionally fused with a portion of GUC YC2 transmembrane domain while still permitting extracellular secretion of soluble GUCYC2 untethered to the cell membrane.
  • the soluble GUCYC2 when expressed in a cell, the soluble GUCYC2 can be secreted by the cell. It is understood that the secretion of soluble GCC is facilitated by a signal sequence and that a nucleic acid encoding soluble GCC would code for either an endogenous or exogenous signal sequence.
  • a soluble GUCYC2 may be linked to a signal peptide such as a GUCYC2 signal peptide and include additional amino acids.
  • a secretion signal As used herein, “a secretion signal”, “a secretion peptide, “a signal peptide” and “signal sequence” are used interchangeably and meant to refer to an amino acid sequence of a protein which when present results in the transportation and secretion of the protein to the exterior of the cell.
  • Secretion signals are typically cleavable hydrophobic segments of a precursor protein at or near the N terminus of the precursor protein. In the secretion process, such secretion signals are enzymatically removed to result in the secretion of a mature form of the protein, i.e. a form of the protein lacking the secretion signal.
  • the secretion signal is a GCC secretion signal derived from GCC protein.
  • the GCC secretion signal is the N-terminus signal peptide comprising residues 1 to about residues 21, 22 or 23 of GUCYC2.
  • the secretion signal is derived for a source different from GUCYC2 (an “exogenous signal sequence”) and replaces the endogenous signal sequence.
  • the coding sequence of the GCC antigen including the signal sequence is used intact.
  • a nucleotide sequence encoding the signal sequence from another source is linked to the coding sequence GCC in place of the naturally occurring signal sequence and in frame with the rest of the protein.
  • the signal sequence may be any such sequence which is functional in the cells of the individual to whom the genetic construct is administered.
  • GUICY2C-expressing tumors refers to tumors expressing guanylyl cyclase C or “GCC”. Such tumor/cancer cells generally originate within the gastrointestinal tract and include but are not limited to tumors/cancer cells of esophageal, gastric, pancreatic, or colorectal origin. Such tumors may be primary or metastatic. As used herein, the term "colorectal tumor” or “cancer occurring within the colorectal tract” is meant to include the well-accepted medical definition that defines colorectal cancer as a medical condition characterized by cancer of cells of the intestinal tract below the small intestine (i.e.
  • colon the large intestine
  • colon including the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon, and rectum.
  • colon cancer or “cancer occurring within the colorectal tract” is meant to further include medical conditions which are characterized by cancer of cells of the duodenum and small intestine (jejunum and ileum).
  • the definition of colorectal cancer used herein is more expansive than the common medical definition but is provided as such since the cells of the duodenum and small intestine also contain GCC.
  • stomach cancer or “gastric cancer” are meant to include the well-accepted medical definition that defines stomach cancer as a medical condition characterized by cancer of cells of the stomach.
  • esophageal cancer is meant to include the well-accepted medical definition that defines esophageal cancer as a medical condition characterized by cancer of cells of the esophagus.
  • pancreatic cancer is meant to include the well-accepted medical definition that defines pancreatic cancer as a medical condition characterized by cancer of cells of the pancreas.
  • a “primary tumor” is one confined to the original tissue of origin. This is as opposed to a metastatic tumor which has disseminated from the primary tissue of origin to other organs.
  • outside of the colorectal tract refers to organs not within the colorectal tract.
  • the deleted adenoviral genes are replaced by a gene expression cassette which drives expression of the foreign transgene.
  • These deleted vectors are usually constructed from plasmids or Ad DNA containing the genetically modified Ad genome, and the vectors are grown up on complementing cell lines such as HEK293, PER.C6, or N52.E6 which retain and express the necessary essential genes.
  • a functional mature GCC protein is produced when the signal sequence is excised.
  • the functional mature GCC protein typically includes amino acid residues 22-1073 of SEQ ID NO:2, amino acid residues 23-1073 of SEQ ID NO:2 or amino acid residues 24- 1073 of SEQ ID NO:2.
  • the mature GCC proteins this comprises the extracellular domain, the transmembrane domain, the kinase homology domain and the guanylyl cyclase catalytic domain.
  • the extracellular domain of the functional mature GCC protein typically includes about 330-423 amino acid residues including the sequence from amino acid residue 54 to amino acid residue 384 of the functional mature GCC protein.
  • the extracellular domain may include the sequence from amino acid residues 22, 23 or 24 to amino acid residues 420 to 435 of the functional mature GCC protein.
  • the sequence of extracellular domain of the functional mature GCC protein may include the sequence from amino acid residues 22 to amino acid residues 435 of the functional mature GCC protein or a 330-422 amino acid residue fragment of the sequence from amino acid residues 22 to amino acid residues 435 of the functional mature GCC protein that includes the sequence from about amino acid residues 54 to about amino acid residue 384 of the functional mature GCC protein, such as for example the sequence from amino acid residues 22, 23 or 24 to amino acid residues 420 to 435 of the functional mature GCC protein.
  • the extracellular domain of GCC does not have homology with guanylyl cyclases A, B and G which have broad tissue distribution and different ligand specificities.
  • the transmembrane domain of the functional mature GCC protein typically includes about 16-23 amino acid residues including the sequence from about amino acid residue 436 to about amino acid residue 452 of the functional mature GCC protein.
  • the transmembrane domain may include the sequence from about amino acid residue 431 to about amino acid residue 454 of the functional mature GCC protein or a 16-22 amino acid fragment of the sequence from about amino acid residue 431 to about amino acid residue 454 of the functional mature GCC protein such as for example the sequence from about amino acid residue 436 to about amino acid residue 452 of the functional mature GCC protein or the sequence from about amino acid residue 431 to about amino acid residue 454 of the functional mature GCC protein.
  • the kinase homology domain of the functional mature GCC protein typically includes about 237-260 amino acid residues including the sequence from about amino acid residue 508 to about amino acid residue 745 of the functional mature GCC protein.
  • the kinase homology domain may include the sequence from about amino acid residue 489 to about amino acid residue 749 of the functional mature GCC protein or a 237-259 amino acid fragment of the sequence from about amino acid residue 489 to about amino acid residue 749 of the functional mature GCC protein such as for example the sequence from about amino acid residue 508 to about amino acid residue 745 of the functional mature GCC protein or the sequence from about amino acid residue 489 to about amino acid residue 749 of the functional mature GCC protein.
  • the guanylyl cyclase catalytic domain of the functional mature GCC protein typically includes about 186-257 amino acid residues including the sequence from about amino acid residue 816 to about amino acid residue 1002 of the functional mature GCC protein.
  • the guanylyl cyclase catalytic domain may include the sequence from about amino acid residue 750 to about amino acid residue 1007 of the functional mature GCC protein or a 186-256 amino acid fragment of the sequence from about amino acid residue 750 to about amino acid residue 1007 of the functional mature GCC protein such as for example the sequence from about amino acid residue 816 to about amino acid residue 1002 of the functional mature GCC protein or the sequence from about amino acid residue 750 to about amino acid residue 1007 of the functional mature GCC protein.
  • the soluble GCC of the present invention are preferably expressed as a fusion protein in which soluble GCC and a universal CD4+ T epitope are expressed as a single polypeptide.
  • the sequence encoding the soluble GCC will preferably be linked to the sequence encoding the universal CD4+ T epitope such that an in frame translational fusion of the two regions results.
  • the universal CD4+ helper epitope may be attached at either the N or C terminus of the soluble GCC. If attached at the N terminus it is inserted downstream of the endogenous or an exogenous signal sequence.
  • a truncated GUCYC2 which comprises the GCC signal sequence and extracellular domain of the molecule which in the aggregate consists of about the first 429 amino acid residues of GCC fused at the C terminus to a universal CD4+ helper epitope (PADRE) is exemplified herein.
  • PADRE universal CD4+ helper epitope
  • tumor markers such as GCC are well known in the art.
  • expression may be detected as protein levels or as mRNA levels.
  • Techniques such as qRT-PCR branched oligonucleotide technology, Panomics QuantiGene® 2.0 (Affymetrix, Inc. Santa Clara, Calif.) Quantitative Gene expression reagents and assays, MassARRAY® (Sequenom, Inc.
  • Quantitative Gene Expression systems in situ hybridization using detectable probes such as FISH
  • dot blots assays and other RNA quantitative amplification techniques and Northern Blots are useful for measuring mRNA levels and protein mass spectrometry including protein and peptide fractionation coupled with mass spectrometry, immunohistochemistry using detectable binding agents, immunoassays such as ELISA or Western blots, QProteome FFPE Qiagen Valencia Calif., reverse phase protein microarrays are useful for detecting protein markers presence and levels.
  • US Patent Publication No. 20170049869A1 describes RT-PCT methods of detection as applicable to GCC.
  • US Patent Publication No. 20180355062 describes anti- GCC antibody molecules.
  • Prophylactic and therapeutic vaccines for protecting or treating individuals against primary and/or metastatic GUCY2C-expressing tumors are provided.
  • Compositions useful to make such vaccines and methods of making and using the vaccines are provided.
  • GCC Guanylyl cyclase C
  • the vaccines of the present invention are useful for prophylactic or therapeutic immunization of human patients with GUCY2C-expressing cancers including esophageal, gastric, pancreatic, and colorectal cancer without inducing autoimmunity.
  • Some embodiments provide a modified adenovirus vector-based vaccine for cancer, particularly colorectal cancer, and immunotherapy as well as cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that affect the general population.
  • the vaccine uses a modified version of a recombinant adenovirus vector in which viral protein F35 is included to replace the corresponding adenovirus protein of adenovirus 5.
  • the modified adenovirus vector may be referred to as Ad5.F35 and comprises coding sequences for fusion protein that includes cancer associated protein sequences, such as portions of a cancer associated protein GUCY2C extracellular domain sequences linked to T cell epitopes.
  • the modified adenovirus vector-based anti-GUCY2C vaccine is used to deliver the colorectal cancer protein to immune cells within the body to educate them against colorectal cancer. Some of these educated immune cells may then be able to search for and kill colorectal cancer hiding in the body. Some of these educated immune cells may then be able to produce or induce production of antibodies that target cells expressing the colorectal cancer protein. Some of these educated immune cells may then be able to induce production of antibodies and immune cells that target cells expressing the colorectal cancer protein.
  • Some embodiments provide prime boost method of vaccinating against cancer particularly colorectal cancer cells that express a cancer associated protein such as the colorectal cancer associated protein GUCY2C.
  • a combination of an adenovirus based GUCY2C vaccine with a modified Listeria monocytogenes produces immune responses superior to those using either vaccine alone.
  • Effective immune responses against GUCY2C are useful to treat any cancer that expresses such proteins such as metastatic colorectal cancer, a disease that is typically fatal as well as several other cancers that express the protein GUCY2C such as pancreatic, stomach, and esophageal.
  • Adenoviruses represent a widely used viral- vectored platform for vaccine design.
  • Ad5 adenovirus
  • DNA based vaccines against GUCY2C generate GUCY2C-specific T cell responses yielding antitumor immunity.
  • Recombinant adenovirus particles expressing a chimeric protein comprising GCC ECD linked to CD4+ helper epitopes are disclosed in co-pending application Serial No. 13/120, 144, which is incorporated herein by reference.
  • the various GUCY2C ECD T-cell epitope constructs described herein may be used with the adenovirus Ad5 vector to produce anti- GUCY2C vaccines.
  • Ad vectors for gene expression in humans rely on serotype 5 Ad vectors.
  • Adenovirus infection is initiated by the attachment of Ad 5 to the cell surface via the fiber protein (Shenk, T. 1996 Fields Virology, Volume 2, Fields, BN et al. (Eds), Volume 2, Lippincott-Raven, Philadelphia, PA, 2111-2148).
  • the distal C- terminal domain of the trimeric fiber molecule ends in a "Knob” that binds to a specific cellular receptor, which for Ad5 is the coxsackie adenovirus receptor (CAR) (Bergelson, JM et al. Science, 275, 1320-1323).
  • CAR coxsackie adenovirus receptor
  • After binding the cellular internalization interact in an event which is independent of the virus attachment, Arg-Gly-Asp (RGD-motifs) in the penton base with cellular integrins.
  • Ad5 is a natural human pathogen, producing mild infections in nearly the entire human population (Yu, B., et al. (2012) J Med Virol 84(9): 1408-1414). These natural exposures induce Ad5-specific neutralizing antibodies (NAbs) that limit reinfection or Ad5-based vaccination by preventing infection of host cells, a necessary step in target antigen expression and induction of immune responses (Priddy, F. H., et al. (2008) Clin Infect Dis 46(11): 1769-1781; Schirmbeck, R., et al. (2008) Mol Ther 16(9): 1609-1616; Small, J. C., et al. (2014) J Leukoc Biol 96(5): 821-831).
  • NAbs Ad5-specific neutralizing antibodies
  • Ad5 NAbs target the fiber molecule on the surface of Ad5 (Cheng, C., et al. (2010) J Virol 84(1): 630-638). This might suggest that replacement of the fiber molecule in Ad5 with the fiber molecule from the B group adenovirus Ad35 (to which few human subjects have natural immunity) might produce a chimeric Ad5 viral vector (known as Ad5.F35) that is not affected by naturally-occurring Ad5 immunity.
  • Ad5.F35 chimeric Ad5 viral vector
  • Sumida et al. have found that functionally significant Ad5-specific NAbs are directed primarily against the Ad5 hexon protein. (Sumida et al, Journal of Immunology (2005) 174 (11) 7179-7185). Hong et al. have reported significant neutralizing effect with respect to antibodies directed to the penton base. (Hong S.S. et al. J. Virol. 2003; 77: 10366-
  • Vectors containing B-group Ad fibers use CD46 for initial cellular attachment (Gaggar, A., et al. (2003). Nat. Med. 9: 1408 - 1412). In humans, CD46 is expressed on all nucleated cells at a low level.
  • AD5.F35 vaccination to a test antigen did not induce immunosuppression in CD46 transgenic mice and noted that their results might be antigen specific (DiPaolo N, et al. Mol Ther. 2006;13(4):756-765).
  • a study in primates however found that an Ad5.Fib35 with a measles haemagglutinin vaccine insert had a reduced insert specific humoral and cellular immune response than animals similarly immunized with Ad5 (Ophorst, O. J., et al. (2004). Vaccine 22: 3035 - 3044).
  • the present invention comprises a chimeric adenoviral vaccine vector Ad5.F35 comprising: a) an Ad5.F35 vector; and a gene expression cassette comprising: i) a nucleic acid encoding a soluble human GUCY2C domain; ii) a heterologous promoter operatively linked to the nucleic acid encoding the soluble human GUCY2C domain; and iii) a universal CD4+ helper epitope as well as vaccines and methods relying thereon.
  • the adenoviral vector of the invention can be replication-competent. Preferably, however, the adenoviral vector is replication-deficient in host cells.
  • EP 1 693 459 Al, WO 2000/073478 A9 and EP 1 322 774 A2 which are each incorporated herein by reference, describe chimeric Ad5.F35 vectors to modify the tropism (cell/tissue targeted by the virus) of Ad5. None describe insensitivity to Ad5 neutralizing immunity.
  • chimeric Ad5.Fib35 virus vectors has been described by Shayakhmetov et al. via a twostep PCR approach in which three fragments are amplified: (i) the Ad5 fiber non-translated region and the first 132 bp of the fiber tail domain; (ii) the Ad35 shaft and knob domains; and; (iii) the Ad5E4 region including the Ad5 fiber poly adenylation signal. After purification of the resultant fragments, they are combined and subjected to an additional PCR reaction primed by forward and reverse primers directed to the correct ends of the chimeric fiber.
  • the resultant amplified fragment is then substituted into a donor plasmid by ligation and the substitution of the chimeric fiber is performed by recombination with the vector genome contained within a plasmid in a Rec-i- E. coli strain BJ5183.
  • clones verified to be correct were digested with the restriction enzyme Pad to release the viral genomes and transfected onto 293 cells (Shayakhmetov DM et al. J Virol 2000; 74: 2567-2583).
  • EP1550722B1 describes a similar procedure of direct replacement of the Ad5 fiber sequence in a donor vector and subsequent recombination and amplification.
  • Ad vectors carrying a foreign gene insert.
  • the first method is the in vitro ligation method involving the ligation of a DNA fragment obtained by restriction digesting of a plasmid carrying the foreign gene insert flanked by Ad sequences with a DNA fragment representing the rest of Ad genome (Stow ND. J Virol. 1981; 37:171-80).
  • the second method consisted of homologous recombination in permissive cell lines between two plasmids the shuttle plasmid carrying the foreign gene insert flanked by Ad sequences for site-specific insertion and the genomic plasmid carrying almost the entire Ad genome. (Bett AJ, et al. Proc Natl Acad Sci U S A. 1994; 91:8802-6. These classic methods of vector construction usually have low efficiency and sometimes can be contaminated with the parental virus.
  • This strategy involves homologous recombination between Ad DNA and the yeast artificial chromosome (YAC) vector containing sequences from the left and the right termini of Ad genome, resulting in the generation of a yeast artificial chromosome containing an infectious copy of Ad genome. Transfection of the excised Ad genome into appropriate cells results in generation of infectious virions.
  • YAC yeast artificial chromosome
  • Ad vectors are generated as a result of Cre- mediated site-specific recombination between two plasmids after their co-transfection into a suitable cell line expressing Cre recombinase. Frequency of vector generation using Cre/LoxP-based system has been found to be 30 to 100-fold higher compared to the traditional homologous recombination methods.
  • a functional mature GCC protein is produced when the signal sequence is excised.
  • the functional mature GCC protein typically includes amino acid residues 22-1073 of SEQ ID NO:2, amino acid residues 23-1073 of SEQ ID NO:2 or amino acid residues 24- 1073 of SEQ ID NO:2.
  • the mature GCC proteins comprises the extracellular domain, the transmembrane domain, the kinase homology domain and the guanylyl cyclase catalytic domain.
  • Vaccines comprise soluble truncated forms of GCC protein which comprise extracellular domain of the functional mature GCC protein, which typically includes about 330-423 amino acid residues including the sequence from amino acid residue 54 to amino acid residue 384 of the functional mature GCC protein.
  • the extracellular domain may include the sequence from amino acid residues 22, 23 or 24 to amino acid residues 420 to 435 of the functional mature GCC protein.
  • the sequence of extracellular domain of the functional mature GCC protein may include the sequence from amino acid residues 22 to amino acid residues 435 of the functional mature GCC protein or a 330-422 amino acid residue fragment of the sequence from amino acid residues 22 to amino acid residues 435 of the functional mature GCC protein that includes the sequence from about amino acid residues 54 to about amino acid residue 384 of the functional mature GCC protein, such as for example the sequence from amino acid residues 22, 23 or 24 to amino acid residues 420 to 435 of the functional mature GCC protein.
  • Constructs may also include sequences from the transmembrane domain provided they are not sufficient to function to prevent the soluble GCC construct from becoming anchored in the cell membrane.
  • the transmembrane domain of the functional mature GCC protein typically includes about 16- 23 amino acid residues including the sequence from about amino acid residue 436 to about amino acid residue 452 of the functional mature GCC protein.
  • the transmembrane domain may include the sequence from about amino acid residue 431 to about amino acid residue 454 of the functional mature GCC protein or a 16-22 amino acid fragment of the sequence from about amino acid residue 431 to about amino acid residue 454 of the functional mature GCC protein such as for example the sequence from about amino acid residue 436 to about amino acid residue 452 of the functional mature GCC protein or the sequence from about amino acid residue 431 to about amino acid residue 454 of the functional mature GCC protein.
  • no transmembrane sequences are included.
  • a universal CD4+ helper epitope may be linked to GUCY2C sequences io produce a fusion protein.
  • a universal CD4+ helper epitope is a peptide sequence which is a match for and therefore recognized by multiple HLA types.
  • An example of a universal CD4+ helper epitope is a PADRE (Pan DR epitope peptides).
  • the PADRE peptides forms complexes with at least 15 of the 16 most common types of HLA-DR. Since humans have at least one DR and PADRE binds to many of its types, PADRE has a high likelihood of being effective in most humans.
  • Universal CD4+ helper epitopes, such as PADRE and others are disclosed in U.S. Pat. No. 5,736,142 issued Apr. 7, 1998 to Sette, et al.; U.S. Pat. No. 6,413,935 issued Jul. 2, 2002 to Sette, et al.; and U.S. Pat. No. 7,202,351 issued Apr. 10, 2007 to Sette, et al and WO 1995007707 Al.
  • the universal HLA-DR epitope PADRE (KXVAAWTLKA) has been described.
  • PADRE When PADRE is fused to a protein antigen several investigators have used the peptide sequence AKFVAAWTLKAAA expressed in frame with the antigen of interest.
  • T cell epitope present in the 33 kDa C-terminal region of P. vivax MSP1 DYDVVYLKPLAGMYK (SEQ ID NO: 12) has also been found to elicit a strong immune response in non-human primates with different class II HLA haplotypes (Rosa et. al. Microbes Infect 2006, 8:2130-7;
  • the CD4+ T cell epitope may be derived from tetanus toxin for example TT 830-844 QYIKANSKFIGITEL (SEQ ID NO: 19), and TT 947-967 FNNFTVSFWLRVPKVSASHLE (SEQ ID NO:20)
  • the CD4+ T cell epitope may be derived from Influenza hemagglutinin for example influenza hemagglutinin residues 306-318 PKYVKQNTLKLAT (SEQ ID NO:26). (Busch et al., Int. Immunol. 2, 443-451 (1990); Mom et al. BMC Immunol 2005; 6:24).
  • the CD4+ T cell epitope may be derived from Hepatitis B surface antigen (HBsAg) (Litjens et al. . J Immunol Methods 2008; 330:1-11).
  • HSAg Hepatitis B surface antigen
  • the CD4+ T cell epitope may be derived from outer membrane proteins (OMPs) of bacterial pathogens (such as Anaplasma marginals) (Macmillan H, Norimine J, Brayton K A, Palmer G H, Brown W C. Physical linkage of naturally complexed bacterial outer membrane proteins enhances immunogenicity. Infect Immun 2008; 76:1223-9).
  • OMPs outer membrane proteins
  • the CD4+ T cell epitope may be derived from the VP1 capsid protein from enterovirus 71 (EV71) strain 41 for example residues 66-77 IETRCVLNSHSTAET (SEQ ID NO:27), residues 145-159 EVVPQLLQYMFVPPG (SEQ ID NO:28), and residues 247-261 LVVRIYMRMKHVRAW (SEQ ID NO:29).
  • enterovirus 71 EV71
  • enterovirus 71 enterovirus 71
  • SEQ ID NO:27 residues 66-77 IETRCVLNSHSTAET
  • residues 145-159 EVVPQLLQYMFVPPG SEQ ID NO:28
  • residues 247-261 LVVRIYMRMKHVRAW SEQ ID NO:29.
  • the CD4+ T cell epitope may be derived from EBV BMLF1 (Schlienger K, Craighead N, Lee K P, Levine B L, June C H. Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. Blood 2000; 96:3490-8; Neidhart J, Allen K O, Barlow D L, Carpenter M, Shaw D R, Triozzi PL, Conry R M. Immunization of colorectal cancer patients with recombinant baculovirus- derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor.
  • Ep-CAM baculovirus- derived KSA
  • the CD4+ T cell epitope may be derived from EBV LMPI for example LMP 1159-175 YLQQNWWTLLVDLLWLL (SEQ ID NO:30) Kobayashi et al. Cancer Res 2008; 68:901-8).
  • the CD4+ T cell epitope may be derived from HIV Gag p24 for example Gag 131-15 NYPIVQNIQGQMVHQAISPR (SEQ ID NO:31), Gag 211-230 EWDRVHPVHAGPIAPGQMRE (SEQ ID NO:32), Gag 241-260 STLQEQIGWMTNNPPIPVGE (SEQ ID NO:33), Gag 263-277 KRWIILGLNKIVRMY (SEQ ID NO:34), Gag 271-290 NKIVRMYSPTSILDIRQGPK (SEQ ID NO:35), Gag 291-310 EPFRDYVDRFYKTLRAEQAS (SEQ ID NO:36), Gag 301-320YKTLRAEQASQEVKNWMTET (SEQ ID NO: 37), Gag 321-340 LLVQNANPDCKTILKALGPA (SEQ ID NO:38), Gag 331-350 KTILKALGPAATLEEMMTAC (SEQ ID NO:39), (Pajo
  • the CD4+ T cell epitope may be derived from Adenovirus 5 hexon protein for example the residues found at position 556 to 580 VPFHIQVPQKFFAIKNLLLLPGSYT (SEQ ID NO:40), residues 56-80 VTTDRSQRLTLRFIPVDREDTAYSY (SEQ ID NO:41), residues 316-335 GQQSMPNRPNYIAFRDNFIG (SEQ ID NO:42) and residues 906-930 EVDPMDEPTLLYVLFEVFDVVRVHRPHR (SEQ ID NO:43) (Leen et al. J Virol 2008; 82:546-54).
  • Adenovirus 5 hexon protein for example the residues found at position 556 to 580 VPFHIQVPQKFFAIKNLLLLPGSYT (SEQ ID NO:40), residues 56-80 VTTDRSQRLTLRFIPVDREDTAYSY (SEQ ID NO:41), residues 316-335 GQQ
  • the CD4+ T cell epitope may be derived from Vaccinia virus proteins for example the F17R protein residues at residues 21 through 29 (YLVLKAVKV) and the A10L protein residues at residues 20-28 FRIVSTVLP. (Calvo-Calle et al. PLoS Pathog 2007; 3:1511-29) Calvo-Calle identified >25 CD4+ T cell epitopes for multiple MHC-II haplotypes from 24 different vaccinia proteins.
  • the CD4+ T cell epitopes are derived from Mycobacterium tuberculosis heat shock protein (Liu D W, Tsao Y P, Kung J T, Ding Y A, Sytwu H K, Xiao X, Chen S L. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000; 74:2888-94.)
  • the CD4+ T cell epitopes are derived from the Fc portion of IgG (You Z, Huang X F, Hester J, Rollins L, Rooney C, Chen S Y. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway. J Immunol 2000; 165:4581-91).
  • the CD4+ T cell epitopes are derived from lysosomal targeting signal of the human LAMP-1 protein (Su Z, Vieweg J, Weizer A Z, Dahm P, Yancey D, Turaga V, Higgins J, Boczkowski D, Gilboa E, Dannull J. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 2002; 62:5041-8).
  • a sample of HLA haplotypes as well as representative CD4+ T cell epitopes for the indicated HLA molecule include, but are not limited to, the following:
  • HLA-DR*1101 Tetanus Toxoid peptide residues 829-844, Hemagglutinin peptide residues 306-318 (Moro M, Cecconi V, Martinoli C, Dallegno E, Giabbai B, Degano M, Glaichenhaus N, Protti M P, Dellabona P, Casorati G. Generation of functional HLA- DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides. BMC Immunol 2005; 6:24.)
  • HLA-DRB 1*0101 (DR1) Tetanus Toxoid peptide residues 639-652, 830-843 or 947- 967 and 14 other tetanus toxoid peptides (BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond D J. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DRl transgenic mice: dependence on HLA class II restricted T(H) response.
  • Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin- specific CD4+ T cells and suggests HLA-based differences in epitope recognition. Int Immunol 2007; 19:1291-301).
  • HLA-DRBl*0301 EV71 VP1 residues 145-159 or 247-261 and 5 different tetanus toxoid peptides (Wei Foo D G, Macary P A, Alonso S, Poh C L. Identification of Human CD4(+) T-Cell Epitopes on the VP1 Capsid Protein of Enterovirus 71. Viral Immunol 2008; and James E A, Bui J, Berger D, Huston L, Roti M, Kwok W Pooh. Tetramer- guided epitope mapping reveals broad, individualized repertoires of tetanus toxin- specific CD4+ T cells and suggests HLA-based differences in epitope recognition. Int Immunol 2007; 19:1291-301).
  • HLA-DRB 1*0405 EV71 VP1 residues 145-159 or 247-261 (Wei Foo D G, Macary P A, Alonso S, Poh C L. Identification of Human CD4(+) T-Cell Epitopes on the VP1 Capsid Protein of Enterovirus 71. Viral Immunol 2008).
  • HLA-DRB 1* 1301 EV71 VPI residues 145-159 or 247-261 (Wei Foo D G, Macary P A, Alonso S, Poh C L. Identification of Human CD4(+) T-Cell Epitopes on the VP 1 Capsid Protein of Enterovirus 71. Viral Immunol 2008).
  • HLA-DR9 Epstein Barr virus (EBV) latent membrane protein 1 (LMP1) residues 159-175 (Kobayashi H, Nagato T, Takahara M, Sato K, Kimura S, Aoki N, Azumi M, Tateno M, Harabuchi Y, Celis E. Induction of EBV-latent membrane protein 1-specific MHC class Il-restricted T-cell responses against natural killer lymphoma cells. Cancer Res 2008; 68:901-8).
  • EBV Epstein Barr virus
  • HLA-DRB 1*0401 15 different Tetanus Toxoid peptides (James E A, Bui J, Berger D, Huston L, Roti M, Kwok W W. Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin- specific CD4+ T cells and suggests HLA-based differences in epitope recognition. Int Immunol 2007; 19:1291-301).
  • HLA-DRB 1*1501 7 different Tetanus Toxoid peptides (James E A, Bui J, Berger D, Huston L, Roti M, Kwok W W. Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin- specific CD4+ T cells and suggests HLA-based differences in epitope recognition. Int Immunol 2007; 19:1291-301).
  • HLA-DRB5*0101 8 different Tetanus Toxoid peptides (James E A, Bui J, Berger D, Huston L, Roti M, Kwok W W. Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition. Int Immunol 2007; 19:1291-301).
  • AD5.F35-GUCY2C, AD5.F35-GUCY2C ECD , AD5.F35-GUCY2C- universal T cell epitope, AD5.F35-GUCY2C ECD -universal T cell epitope are used interchangeably to refer to A45.F35 adenovirus vectors with the genetic insert encoding GUCY2C ECD linked to a universal T cell epitope such that infection with the vaccine results in the GUCY2C ECD linked to a universal T cell epitope fusion protein being expressed and secreted by infected cells.
  • the universal T cell epitope of the AD5.F35-GUCY2C vaccine is the universal T cell epitope PADRE.
  • AD5.F35-GUCY2C- PADRE and AD5.F35-GUCY2C ECD -PADRE.
  • All references to methods of using AD5.F35-GUCY2C vaccine are intended to describe the general AD5.F35-GUCY2C vaccines and the AD5.F35-GUCY2C ECD -PADRE vaccine in particular.
  • aspects of the invention include methods of treating individuals who have a cancer/tumor expressing GUCY2C.
  • the treatment is provided systemically.
  • an immune response that specifically targets the cancer cells expressing GUCY2C can be induced in the peripheral compartments of the individual's immune system.
  • the vaccines treat primary or metastatic disease including identified metastatic disease as well as any undetected metastasis, such as micrometastasis.
  • the vaccines provide an adjuvant therapeutic treatment with the ordinary treatment provided upon diagnosis of cancer involving mucosal tissue.
  • one skilled in the art can diagnose a cancer or tumor as expressing GUCY2C. Detection of metastatic disease can be performed using routine methodologies although some minute level of cancer may be undetectable at the time of initial diagnosis of cancer. Typical modes of therapy include surgery, chemotherapy or radiation therapy, or various combinations.
  • Vaccines targeting GUCY2C provide an additional weapon with die advantage of not attacking normal tissue but selectively detecting and eliminating cancer cells originating from immunologically protected compartments expressing GUCY2C.
  • an individual is diagnosed as having cancer and the cancer is identified as expressing GUCY2C.
  • a AD5.F35-GUCY2C vaccine expressing soluble GUCY2C linked to a CD4+ helper epitope is administered to the patient alone or as part of a treatment regimen which includes surgery, and/or radiation treatment anchor administration of other anti-cancer agents.
  • the vaccines may also be used prophylactically in individuals who are at risk of developing as GUCY2C cancers/tumors. Previous diagnosis with primary disease which has been removed or in remission places the individual at higher risk.
  • Individuals who are at risk of developing as mucosal tissue cancer may be administered vaccines in order to induce an immune response which will eliminate cancer cells prior to the individual having detectable disease.
  • such individuals may also be identified for CD4+ helper epitope type.
  • a vaccine administered to the individual which contains the protein or genetic code for die mucosally restricted antigen and one or more CD4+ helper epitopes which are recognized by the individual.
  • Vaccines comprise a pharmaceutically acceptable carrier in combination with the active agent which may be. a nucleic acid molecule, a vector comprising a nucleic acid molecule such as a virus, a protein or cells.
  • the active agent which may be. a nucleic acid molecule, a vector comprising a nucleic acid molecule such as a virus, a protein or cells.
  • Pharmaceutical formulations are well known and pharmaceutical compositions comprising such active agents may be routinely formulated by one having ordinary skill in the art. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, a standard reference text in this field.
  • the present invention relates to an injectable pharmaceutical composition that comprises a pharmaceutically acceptable carrier and the active agent.
  • the composition is preferably sterile and pyrogen free.
  • the active agent can be formulated as a solution, suspension, emulsion or lyophilized powder in association with a pharmaceutically acceptable vehicle.
  • a pharmaceutically acceptable vehicle examples include water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils may also be used.
  • the vehicle or lyophilized powder may contain additives that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives). The formulation is sterilized by commonly used techniques.
  • An injectable composition may comprise the immunogen in a diluting agent such as, for example, sterile water, electrolytes/dextrose, fatty oils of vegetable origin, fatty esters, or polyols, such as propylene glycol and polyethylene glycol.
  • a diluting agent such as, for example, sterile water, electrolytes/dextrose, fatty oils of vegetable origin, fatty esters, or polyols, such as propylene glycol and polyethylene glycol.
  • the injectable must be sterile and free of pyrogens.
  • the vaccines may be administered by any means that enables the immunogenic agent to be presented to the body’s immune system for recognition and induction of an immunogenic response.
  • Pharmaceutical compositions may be administered parenterally, i.e., intravenous, subcutaneous, intramuscular.
  • Dosage varies depending upon the nature of the active agent and known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired.
  • An amount of immunogen is delivered to induce a protective or therapeutically effective immune response. Those having ordinary skill in the art can readily determine the range and optimal dosage by routine methods.
  • Lm-GUCY2C Listeria monocytogenes expressing GUCY2C
  • Fig. 11 infected macrophages
  • Fig. 12 GUCY2C-specific T cell responses following Ad5
  • Fig. 13 DNA vaccination
  • Lm-GUCY2C-based vaccination regimens are expected to induce robust antitumor efficacy in patients with GUCY2C-expressing cancers, including but not limited to, colorectal, gastric, esophageal, pancreatic, and salivary.
  • LLO [actin-assembly inducing protein; (actA)]; or other PrfA-dependent promoters.
  • b Employs GUCY2C extracellular domain (amino acids ⁇ 23 to ⁇ 429) fused to the C-terminus of LLO (amino acids -1 to -420) to promote cytosolic secretion.
  • Lm-ActA-GUCY2C a. Employs a strong Lm promoter, such as hly [listeriolysin O;
  • Lm-ActA-Synl8x5-GUCY2C a. Employs a strong Lm promoter, such as hly [listeriolysin O;
  • LLO [actin-assembly inducing protein
  • actA acta [actin-assembly inducing protein
  • actA acta [actin-assembly inducing protein
  • ActA acta [actin-assembly inducing protein
  • ActA acta [actin-assembly inducing protein
  • ActA acta [actin-assembly inducing protein
  • other PrfA-dependent promoters b.
  • a fusion protein consisting of GUCY2C extracellular domain (amino acids ⁇ 23 to ⁇ 429) at the C-terminus connected to the Synl8x5 sequence to enhance fusion protein expression (US Patent US20180030457A1) and a modified form of ActA known as ActAN100* at the N-terminus (described in US Patent US20180030457A1) to promote cytosolic secretion.
  • Other variations of Lm-GUCY2C that include a promoter driving expression of GUCY2
  • these may employ various Lm stain “backbones” including, but not limited to,
  • KBMA killed but metabolically active
  • the Lm vector comprises any one of several difference GUCY2C inserts such as those described in section 4.2 above.
  • coding sequences for GUCY2C ECD free of universal epitopes linked thereto are inserted into an Lm vector.
  • GUCY2C inserts such as those described in section 4.2 may be linked to the universal T cell epitopes described in section 4.3.
  • Lm-GUCY2C, Lm-GUCY2C ECD , Lm-GUCY2C-universal T cell epitope and Lm-GUCY2C ECD -universal T cell epitope are used interchangeably to refer to Lm vectors with the genetic insert encoding GUCY2C ECD linked to a universal T cell epitope such that infection with the vaccine results in the GUCY2C ECD linked to a universal T cell epitope fusion protein being expressed and secreted by infected cells.
  • Lm-GUCY2C-PADRE and Lm-GUCY2C ECD -PADRE are used interchangeably to refer to such embodiments which comprise PADRE.
  • aspects of the invention include methods of treating individuals who have a cancer/tumor expressing GUCY2C.
  • the treatment is provided systemically.
  • an immune response that specifically targets the cancer cells expressing GUCY2C can be induced in the peripheral compartments of the individual's immune system.
  • the vaccines treat primary or metastatic disease including identified metastatic disease as well as any undetected metastasis, such as micrometastasis.
  • the vaccines provide an adjuvant therapeutic treatment with the ordinary treatment provided upon diagnosis of cancer involving mucosal tissue.
  • one skilled in the art can diagnose a cancer or tumor as expressing GUCY2C. Detection of metastatic disease can be performed using routine methodologies although some minute level of cancer may be undetectable at the time of initial diagnosis of cancer. Typical modes of therapy include surgery, chemotherapy or radiation therapy, or various combinations.
  • Vaccines targeting GUCY2C provide an additional weapon with die advantage of not attacking normal tissue but selectively detecting and eliminating cancer cells originating from immunologically protected compartments expressing GUCY2C.
  • an individual is diagnosed as having cancer and the cancer is identified as expressing GUCY2C.
  • a AD5.F35-GUCY2C vaccine expressing soluble GUCY2C linked to a CD4+ helper epitope is administered to the patient alone or as part of a treatment regimen which includes surgery, and/or radiation treatment and/or administration of other anti-cancer agents.
  • an individual is diagnosed as having cancer and the cancer is identified as expressing GUCY2C.
  • An Lm-GUCY2C vaccine expressing soluble GUCY2C is administered to the patient alone or as part of a treatment regimen which includes surgery, and/or radiation treatment and/or administration of other anti-cancer agents.
  • an individual is diagnosed as having cancer and the cancer is identified as expressing GUCY2C.
  • a prime-boost method is undertaken using both an adenovirus vector-based anti--GUCY2C vaccine and an Lm vector-based anti-GUCY2C vaccine sequentially in combination.
  • the individual is administered an adenovirus vector that expresses a soluble from of GUCY2C first and subsequently an Lm vector-based anli-GUCY2C vaccine.
  • the individual is preferably administered an AD5.F35-GUCY2C vaccine first and subsequently an Lm GUCY2C vaccine but the vaccine may be delivered in reverse order.
  • the shortest interval between the first vaccination and the second is about 2-4 weeks.
  • the preferred interval is about 4-6 weeks.
  • the interval may be between up to 12 months.
  • the vaccine combination therapy may be administered in combination with surgery, and/or radiation treatment and/or administration of other anti- cancer agents.
  • the vaccines may also be used prophylactically in individuals who are at risk of developing as GUCY2C cancers/tumors. Previous diagnosis with primary disease which has been removed or in remission places the individual at higher risk.
  • GUCY2C Individuals who are at risk of developing cancer that express GUCY2C may be administered vaccines in order to induce an immune response which will eliminate cancercells prior to the individual having detectable disease.
  • Vaccines according to some embodiments comprise a pharmaceutically acceptable carrier in combination with the active agent which may be an adenovirus vector or an Lm vector.
  • the active agent which may be an adenovirus vector or an Lm vector.
  • Pharmaceutical formulations are well known and pharmaceutical compositions comprising such active agents may be routinely formulated by one having ordinary skill in the art. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, a standard reference text, in this field.
  • the present invention relates to an injectable pharmaceutical composition that comprises a pharmaceutically acceptable carrier and the active agent.
  • the composition is preferably sterile and pyrogen free.
  • the active agent can be formulated as a solution, suspension, emulsion or lyophilized powder in association with a pharmaceutically acceptable vehicle.
  • a pharmaceutically acceptable vehicle examples include water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils may also be used.
  • the vehicle or lyophilized powder may contain additives that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives). The formulation is sterilized by commonly used techniques.
  • An injectable composition may comprise the immunizing agent in a diluting agent such as, for example, sterile water, electrolytes/dextrose, fatty oils of vegetable origin, fatty esters, or polyols, such as propylene glycol and polyethylene glycol.
  • a diluting agent such as, for example, sterile water, electrolytes/dextrose, fatty oils of vegetable origin, fatty esters, or polyols, such as propylene glycol and polyethylene glycol.
  • the injectable must be sterile and free of pyrogens.
  • the vaccines may be administered by any means that enables the immunogenic agent to be presented to the body’s immune system for recognition and induction of an immunogenic response.
  • Pharmaceutical compositions may be administered parenterally, i.e., intravenous, subcutaneous, intramuscular.
  • Dosage varies depending upon the nature of the active agent and known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of symptoms, kind of concurrent, treatment, frequency of treatment, and the effect desired.
  • An amount of immunogen is delivered to induce a protective or therapeutically effective immune response. Those having ordinary skill in the an can readily determine the range and optimal dosage by routine methods.
  • Ad5-hGCC-PADRE is Limited by Ad5 nAbs
  • Ad5 NAbs are common in most human populations, including ⁇ 40% in the US (Nwanegbo, E., et al. (2004) Clin Diagn Lab Immunol 11(2): 351-357; Barouch, D. H., et al. (2011) Vaccine 29(32): 5203-5209), reducing the immunogenicity of Ad5-based vaccines (Priddy, F. H., et al. (2008). Clin Infect Dis 46(11): 1769-1781).
  • most naturally-occurring Ad5 NAbs target the fiber molecule on the surface of Ad5 (Cheng, C., et al. (2010) J Virol 84(1): 630-638).
  • Ad5.F35 chimeric Ad5 viral vector
  • Ad5.F35- GUCY2C-PADRE is expected to overcome Ad5-specific preexisting immune which was not achieved by dose escalation as predicted by the published literature (Priddy, F. H., et al. (2008). Clin Infect Dis 46(11): 1769-1781).
  • Ad5.F35-hGCC-PADRE an hGCC-PADRE coding sequence was synthesized to produce a mammalian codon-optimized sequence set forth at SEQ ID NO: 3 to increase efficiency of hGCC-PADRE mRNA translation into protein. This construct was subcloned into an Ad5.F35 vector to produce Ad5.F35-hGCC-PADRE.
  • Ad5.F35-hGCC-PADRE is identical to wild type Ad5 (GenBank: AY339865.1), with three exceptions.
  • the hGCC-PADRE expression cassette replaced the El A and E1B regions of Ad5 (nucleotides 455-3512), rendering Ad5.F35-hGCC-PADRE replication incompetent.
  • Ad5.F35 -hGCC-PADRE possesses a large deletion of the E3 region (nucleotides 28586-30464).
  • the E3 region possess several proteins with immunosuppressive functions. All of these E3 proteins are deleted in Ad5.F35-hGCC-PADRE.
  • Ad5 fiber has been replaced with the Ad35 fiber, to minimize neutralization of the vector by pre-existing antibodies to Ad5 in patients.
  • the hGCC-PADRE coding sequence was synthesized to possess a Kozak sequence (GCCGCCACC) immediately 5’ of the initiating ATG and two stop codons immediately after the PADRE sequence.
  • the hGCC-PADRE construct was subclones into the pShuttle vector and then recombined into the Ad5.F35 vector.
  • the Ad5.F35 possesses the human Ad5 sequences encoding all elements required to produce replication-incompetent adenovirus including left and right inverted terminal repeats (ITRs), encapsulation signal for packaging, E2 and E4 regions and late genes.
  • the plasmid lacks the El and E3 proteins and replaces the fiber with Ad35 fiber.
  • a master virus bank of the adenoviral vector Ad5.F35-hGCC-PADRE was produced under GMP conditions in the Vector Production Facility (VPF) of the Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine in Houston, Texas.
  • VPF Vector Production Facility
  • CAGT Center for Cell and Gene Therapy
  • Recombinant adenoviral vector was produced in HEK293 cells, which possess the El genes needed for viral replication. Viable Ad5.F35-hGCC-PADRE virus was formed and collected. The virus underwent two rounds of plaque purification in HEK293 cells. Individual plaques were tested for the presence of hGCC-PADRE DNA, sequenced for hGCC-PADRE cassette accuracy and tested for their ability to produce hGCC-PADRE protein upon infecting cells in vitro. Plaque-purified vector was then expanded in HEK293 cells in tissue culture flask and further amplified used 10-layer cell culture chambers (cell factories).
  • Ad5.F35-hGCC-PADRE was purified by banding in CsCl.
  • the Ad5.F35-hGCC-PADRE Master Virus Bank (MVB) was fully sequenced. A portion of the MVB was vialed for subject administration as part of this trial.
  • the Ad5.F35-hGCC-PADRE vaccine to be used is composed of a recombinant, replication-deficient El/E3-deleted Ad5.F35 virus possessing a GCC-PADRE expression cassette.
  • This vaccine vector employs recombinant human type 5 adenovirus (rAd5), The rAd5 possesses deletions of the early El and E3 regions of the vector, enabling insertion of the GCC-PADRE cassette. E1/E3 deletion renders the virus replication-incompetent increasing safety associated with its clinical use.
  • Ad5.F35-hGCC-PADRE 10 11 , 10 12 , or 5 x 10 12 viral particles formulated in TG buffer (20 mM Tris-HCl, pH 8.0, 25 mM NaCl, 2.5% glycerol) is administered intramuscularly to human patients with selected solid tumors (colorectal, pancreatic, gastric, or esophageal) who are at risk of relapse post definitive surgery and standard adjuvant therapy. Dosages are administered three (3) times. The dosage interval is four (4) weeks apart.
  • T-cell response to Ad5.F35-hGCC-PADRE and humoral immunologic response to GCC are evaluated at 5, 9 and 14 weeks following the first vaccination.
  • the effect of preexisting neutralizing antibody to Ad5 is reduced from that previously observed.
  • Ad5.F35-hGCC-PADRE as a vaccine for gastrointestinal (GI) malignancies (pancreatic, colorectal, esophageal, and gastric adenocarcinomas) who have received surgical resection and standard adjuvant therapy.
  • Patients will be given multiple administrations of Ad5.F35-hGCC-PADRE intramuscularly at 1 of 3 dose levels.
  • Treatment-related toxicity and development of immune responses to GCC will be evaluated at Weeks 5, 9, and 13 after the initial vaccination (Week 1).
  • Primary safety endpoints will examine adverse events (AEs), injection- site reactions and clinically-significant changes in safety laboratory tests.
  • Primary efficacy endpoints include the development of GCC-specific T-cell responses at different dose levels (1011, 1012, and 5x1012 virus particles or vp).
  • objectives include the following:
  • the target final sample size is 72 subjects with evaluable response data. A maximum of 81 subjects with GI adenocarcinomas satisfying all eligibility criteria will be enrolled. We expect to enroll approximately three patients per month. A futility analysis will be performed in each arm after 15 patients have completed treatment with possible discontinuation of arms at that point. Thus, the minimum sample size is 45.
  • Ad5.F35-hGCC-PADRE 1011, 1012, or 5 x 1012 viral particles formulated in TG buffer (20 mM Tris-HCl, pH 8.0, 25 mM NaCl, 2.5% glycerol) and administered intramuscularly.
  • the duration of the treatment cycles (i.e., three doses) will be nine weeks. Subjects will be considered in the treatment period until four weeks after their final study dose, after which they will be in follow-up until death, early discontinuation, or completion of follow-up. Subjects will be followed for the duration of the study until all subjects have reached at least 24 months of follow-up or death. At the conclusion of the study, all remaining subjects will be offered enrollment in a long-term follow-up protocol.
  • the study is open to subjects with solid tumors of the gastrointestinal (GI) tract who are at high risk of recurrence post definitive surgery and/or standard therapy.
  • the subject population includes individuals with colorectal, pancreatic, gastric, or esophageal adenocarcinomas who meet the study eligibility criteria.
  • Pancreatic, colorectal, gastric, and esophageal cancer each represent an ongoing major burden of cancer in the United States, despite improvement in detection and treatment.
  • significant numbers of patients undergo surgical resection and standard therapy with an attempt at cure, but only a fraction (variable by disease histology, stage, and other factors) remain in remission.
  • Adjuvant therapy in the form of chemotherapy and/or radiation therapy in these cases improves overall clinical outcome; however, especially for patients with high-risk features, there is significant room for further improvement.
  • GI malignancies were responsible for 26% of cancer-related deaths in the United States in 2016.
  • pancreatic, esophageal and gastric cancers had the third-, tenth- and sixteenth-highest estimated cancer-related death rate in the US in 2016.
  • the 5-year relative survival rate for GI malignancies varies with disease stage.
  • pancreatic adenocarcinomas have the worst five-year survival rate (7%) for all stages while it is 2% for Stage 4 disease (distant metastasis), 11% for regionally spread disease and 27% for localized disease.
  • This study aims to evaluate a novel vaccine immunotherapy delivered intramuscularly (IM) sequentially at three dose levels to identify the dose that is well tolerated and most suited to induce cellular immune response.
  • IM intramuscularly
  • the ultimate therapeutic goal of this vaccine is to reduce the risk of relapse in subjects with GI adenocarcinoma, at a later stage of clinical development.
  • the primary modality for adjuvant therapy is chemotherapy, such as gemcitabine with capecitabine or 5 -fluorouracil with irinotecan and oxaliplatin (modified FOLFIRNOX)8.
  • the one-year relative survival rate is 20%, with a five-year survival rate of 6%. If a surgical resection can be performed, the average survival rate is 18-20 months.
  • the overall five-year survival rate is about 10% but can reach 20-25% in cases when the tumor is completely removed and when the cancer has not spread to lymph nodes.
  • CRC colorectal cancer
  • neoadjuvant cisplatin In squamous cell carcinomas of the esophagus, neoadjuvant cisplatin was not found to offer an improvement in survival, while neoadjuvant cisplatin and fluorouracil increased 5-year DFS by 10%. In contrast, neoadjuvant chemotherapy (carboplatin & paclitaxel) and radiotherapy in adenocarcinomas of the esophagus had a median OS of 49.4 months, compared with 24 months in the surgery-alone group.
  • neoadjuvant therapy in esophageal cancer are generally beneficial compared to best supportive care, however the relapse remains high and many patients eventually die.
  • pembrolizumab Keytruda®
  • an anti-PD-1 checkpoint immunotherapy was recently approved for patients with PD-L1 -positive cancer of the gastroesophageal junction, though response rates are modest. Given the incidence rate and prognosis of this disease, effective adjuvants with minimal side effects are needed to improve disease outcome.
  • GCC Guanylyl Cyclase C
  • GCC Guanylyl cyclase C
  • cGMP cyclic GMP
  • STs diarrheagenic bacterial heat-stable enterotoxins
  • GCC has been detected in >500 samples of normal intestine, but not in >1,000 extra-gastrointestinal tissues. Moreover, in intestinal epithelial cells, GCC is specifically localized in apical brush border membranes, “outside” the mucosal barrier. This anatomical and functional compartmentalization suggests that, normally, GCC is mucosally-restricted, confirmed by radioligand imaging and biodistribution and immunological studies. Of significance, GCC protein (>200 specimens) and/or mRNA (>900 specimens) were detected in nearly all primary and metastatic human colorectal tumors, with uniform expression by tumor cells, regardless of anatomical location or grade, but not in any extra-GI tumors (>200). Further, GCC is over-expressed by >80% of colorectal tumors. Stringency of expression by intestinal cells and universal over- expression by metastases is underscored by the utility of GCC as a marker for staging pNO patients.
  • GCC In Pancreatic, Gastric and Esophageal Cancers GCC is normally expressed in intestinal epithelial cells and expression is retained during neoplastic transformation of the colorectum both in the regional and metastatic setting. In addition, GCC is found to be expressed in approximately ⁇ 60% of pancreatic, gastric, and esophageal cancers. Disruption of epithelial tight junctions, cell polarity and apical localization of GCC makes it a desired target for systemic agents in tumor tissues while leaving normal tissues unaffected.
  • Ad5 vector vaccines incorporating mouse GCC produce GCC-specific immune responses (antibodies and cytotoxic T cells) in mice. These responses are durable, lasting months after immunization.
  • GCC-specific cytotoxic T cells induced by the vaccine are capable of killing GCC-expressing CRC cells in vitro.
  • Mice with GCC-expressing metastatic colorectal tumors growing in lungs or liver are protected by GCC vaccination: GCC vaccination reduces (or eliminates) the number of detectable metastatic tumors and greatly improves animal survival.
  • these immune responses selectively target metastatic CRC, but do not target normal intestinal tissue expressing GCC, nor do they cause intestinal pathology.
  • GCC-targeted vaccination induces GCC-specific immune responses that can prevent/treat metastatic CRC in murine models, but do so without causing adverse effects.
  • This targeted treatment is anticipated to be highly advantageous clinically compared to established cancer therapies, which have poor efficacy and cause considerable off- target toxicides.
  • Ad5-hGCC-PADRE vaccine was initially evaluated in humans in an open- label, single arm, single dose feasibility study to determine the safety and immunogenicity of Ad5-hGCC-PADRE in early-stage colorectal cancer patients (ClinicalTrials.gov NCT01972737). Subjects received a single intramuscular injection of 10 particles of Ad5- hGCC-PADRE.
  • Subjects in the study were assessed for acute events in the clinic every 10 minutes for 30 minutes after injection and by telephone on Days 3 and 8 following vaccination. Patients also returned to the clinic 30, 90, and 180 days after vaccination for safety assessment. Adverse events were graded according to the CTCAE version 5.0. Among the ten subjects who received Ad5-hGCC-PADRE, 10 (100%) experienced an AE. The most frequently reported vaccine-related AEs were chills/rigor (20%), injection-site pain/swelling (20%), dizziness (10%), diaphoresis (10%), aches (10%) and fever (10%). There were no serious adverse events (SAEs) and no subject died during the study.
  • SAEs serious adverse events
  • Ad5 is a natural human pathogen, producing mild infections in nearly the entire human population. These natural exposures induce Ad5 -specific neutralizing antibodies (nAbs) that prevent reinfection or Ad5 -based vaccination by preventing infection of host cells, a necessary step in target antigen expression and induction of immune responses.
  • Ad5 nAbs were quantified in patient serum collected prior to Ad5-hGCC-PADRE vaccination (Day 0) using an Ad5-GFP reporter virus inhibition bioassay. Titers ranged from ⁇ 10 to >10,000 and an obvious pattern emerged in which half of the patients had titers well below 200 (Ad5 nAb Low) and the other half had titers well above 200 (Ad5 nAb High;).
  • Ad5 nAbs are common in most human populations, including ⁇ 40% in the US (Nwanegbo, E., et al. (2004) Clin Diagn Lab Immunol 11(2): 351-357.; Barouch, D. H., et al. (2011) Vaccine 29(32): 5203-5209), reducing the immunogenicity of Ad5-based vaccines (Priddy, F. H., et al. (2008). Clin Infect Dis 46(11): 1769-1781). Importantly, most naturally-occurring Ad5 nAbs target the fiber molecule on the surface of Ad5 (Cheng, C., et al. (2010) J Virol 84(1): 630-638).
  • Ad5.F35 chimeric Ad5 viral vector
  • Ad5.F35 is advantageous compared to Ad5 by reducing the expected seroprevalence of Ad5.F35 nAbs to ⁇ 25%, without additional safety risk.
  • Ad5.F35-GUCY2C-PADRE is expected to overcome Ad5- specific preexisting immune which was not achieved by dose escalation as predicted by the published literature (Priddy, F. H., et al. (2008). Clin Infect Dis 46(11): 1769-1781).
  • Ad5.F35 The similarity between Ad5 and Ad5.F35 vectors in their immunogenicity, safety, and biodistribution profiles is supported by published nonclinical studies. Indeed, there is some indication that the safety profile may be better with Ad5.F35. While the Ad5.F35 transduction of muscle (the vaccination site) is comparable to Ad5, liver (100Ox), spleen (3x), kidney (100x), heart (10x) and lung (100x) demonstrate significantly lower transduction efficiencies with Ad5.F35 than Ad5. In the context of the lower tropism of Ad5.F35 for liver, Ad5.F35 produced significantly lower elevations in serum proinflammatory cytokines and liver enzymes, suggesting that Ad5.F35 viruses have a better safety profile than Ad5 vectors.
  • Ad5.F35 vectors are significantly less sensitive to Ad5 nAbs than Ad5 vectors, increasing the magnitude of target-antigen- specific immune responses in animals with high Ad5 nAb titers (>200).
  • Ad5.F35 vectors display better biodistribution, safety, and efficacy in the context of Ad5 nAbs than Ad5 vectors.
  • these data suggest that neutralizing immunity to Ad5.F35-hGCC- PADRE will be significantly lower in patients, increasing the rate and magnitude of GCC- specific T-cell responses in human subjects.
  • we have modified the vaccine by replacing the Ad5 fiber molecule with the Ad35 fiber molecule, producing the chimeric viral vector Ad5.F35. This study will examine the safety, immunogenicity, and pre- existing nAbs resistance of Ad5.F35-hGCC-PADRE in patients with GI malignancies.
  • the Ad5.F35-hGCC-PADRE vaccine is composed of a recombinant, replication- deficient El/E3-deleted Ad5.F35 virus possessing a GCC-PADRE expression cassette.
  • This vaccine vector employs recombinant human type 5 adenovirus (rAd5), a stable non- enveloped icosahedral virus with a linear double-stranded DNA genome of ⁇ 38 kb, encoding >30 proteins.
  • the rAd5 possesses deletions of the early El and E3 regions of the vector, enabling insertion of the GCC-PADRE cassette. E1/E3 deletion renders the virus replication-incompetent, increasing safety associated with its clinical use.
  • the GCC-PADRE cassette is composed of the human cytomegalovirus (HCMV) immediate-early promoter driving expression of a fusion product that consists of the extracellular domain of human GCC (residues 1-430) and the CD4+ T-cell epitope PADRE.
  • HCMV human cytomegalovirus
  • the Ad5.F35-hGCC-PADRE vector induces expression of the GCC- PADRE immunogen by infected cells, inducing an immune response against GCC and PADRE.
  • PADRE is included in the vaccine to provide CD4 + T-cell “help” to GCC- specific B and CD8 + T cells, producing superior immunity and antitumor efficacy in preclinical models compared to GCC vaccination without PADRE.
  • the doses selected for this study are based on previous human experience with Ad5-hGCC-PADRE vaccine as well as other Ad5-based vaccine clinical trials.
  • the 1x 10 11 viral particles (vp) dose has been tested as a single administration in the previous Phase 1 clinical trial and was safe and tolerable.
  • the current study examines repeat administration of 1x10 11 vp Ad5.F35-hGCC-PADRE administered intramuscularly (IM) four weeks apart for a total of three injections. Moreover, the study also explores two additional dose levels, also administered three times at four- week intervals. Together, the doses are 1x10 11 vp, 1x10 12 vp, and 5x10 12 vp.
  • the maximum dose of 5x10 12 vp is approximately the highest dose achievable, given limitations on vaccine solubility.
  • the higher dose regimens (1x10 12 and 5x10 12 ) of Ad5.F35-hGCC- PADRE employed in this Phase 2 A study have not been previously tested in humans, other adenovirus-based vaccines have been administered at similar dose levels and were well tolerated.
  • repeat administration of the GCC-PADRE vectors has not been evaluated clinically but other studies have employed repeated administrations of adenovirus-based vaccines using comparable dose levels and were well tolerated.
  • Ad5.F35-hGCC-PADRE the active investigational product to be used in this study, is a replication-deficient adenovirus vaccine against human GCC protein formulated in TG buffer for intramuscular injection.
  • Virus Adenoviridae; non-enveloped, icosahedral virions, 70-90 nm diameter, double-stranded, linear DNA genome. Wild-type virus is lytic, while the El/E3-deleted version in the vaccine is non-replicating.
  • Ad5.F35-hGCC-PADRE is a replication-deficient adenovirus, thus the risk from productive infection is low.
  • the symptoms of wild-type adenoviral infection are fever, rhinitis, pharyngitis, cough and conjunctivitis.
  • Adenoviruses can produce a strong immune response.
  • Adenoviruses do not integrate into the host-cell genome, and Ad5.F35-hGCC-PADRE does not have any additional features that promote integration.
  • the transgene expressed by Ad5.F35-hGCC-PADRE produces a secreted GCC-PADRE fusion protein against which immune responses are generated. These responses are expected to have antitumor activity in patients.
  • Ad5.F35-hGCC-PADRE is an opalescent suspension of recombinant adenovirus type 5 particles that may contain visible particulates of protein origin in a liquid composed of Ad5.F35-hGCC-PADRE viral particles formulated in TG buffer (20 mM Tris-HCl, pH 8.0, 25 mM NaCl, 2.5% glycerol).
  • the vaccine is supplied at the required concentration in vials containing 1.2 mL of a clear colorless sterile solution.
  • Ad5.F35-hGCC-PADRE must be stored below -70°C, protected from light. No vials shall be thawed unless they are being dispensed. Freeze-thaw cycles diminish the vaccine potency and must be avoided.
  • Ad5 adenovirus serotype 5
  • adenovirus capsid is composed of hexon, penton, and fiber proteins
  • NAbs elicited by natural Ad5 infection in humans are directed primarily to the Ad5 fiber, suggesting that strategies to circumvent pre-existing immunity to this element may improve Ad5 -based vaccines.
  • Ad5 NAbs We sought to overcome pre-existing Ad5 NAbs by replacing the Ad5 fiber with that of a rare adenovirus serotype, Ad35 (international seroprevalence -10%), to improve antitumor immunity in mouse models expressing the gastrointestinal (GI) cancer antigen guanylyl cyclase C (GUCY2C).
  • GI gastrointestinal cancer antigen guanylyl cyclase C
  • Ad5-GUCY2C-directed vaccine Ad5-GUCY2C-directed vaccine
  • Ad5-GUCY2C-S1 vaccination of mice induced long-term T-cell- mediated protection against metastatic colorectal cancer in lung and liver.
  • Adenovirus containing mouse extracellular domain (GUCY2C1-429) with the influenza HA107-119 CD4+ T-cell epitope known as site 1 (S1) was described previously (Ad5-GUCY2C-S1).
  • GUCY2C-S1 was cloned into pShuttle and subcloned into the El region of previously generated replication-deficient chimeric adenovirus (Ad5.F35) in which the Ad5 fiber was replaced by the Ad35 fiber to generate Ad5.F35-GUCY2C-S1.
  • adenovirus vaccines used in this study were produced in HEK293 cells and purified by cesium chloride ultracentrifugation under Good Laboratory Practices by the Baylor College of Medicine in the Cell and Gene Therapy Vector Development Lab and certified to be negative for replication-competent adenovirus, mycoplasma, and host cell DNA contamination.
  • In vitro GUCY2C-expression experiments dose-response and timecourse were carried out in A549 (American Type Culture Collection (ATCC)) cells. Virus was added to the cultures at the indicated doses and culture supernntants were collected at the indicated time points.
  • Relative GUCY2C levels were quantified in supernatants by western blot using 2 ⁇ g/mL MS7 mouse anti-GUCY2C monoclonal antibody and 0.1 ⁇ g/mL horseradish peroxidase-conjugated goat antimouse secondary antibody (Jackson Immuno).
  • mice Eight- week old male and female BALB/cJ mice were purchased from the Jackson Laboratory for experiments. Animal protocols were approved by the Thomas Jefferson University Institutional Animal Care and Use Committee (Protocol 02092). For immunizations, mice received 10 10 or 10 11 vp of Ad5-GUCY2C-S1, Ad5.F35-GUCY2C- S1, or Ad5.F35-GFP (control) administered as two 50 pL intramuscular injections, one in each hind limb, using a 0.5 mL insulin syringe.
  • Ad5-GUCY2C-S1 Ad5.F35-GUCY2C- S1
  • Ad5.F35-GFP control
  • ELISpot assays were performed using a mouse interferon-y (IFN- ⁇ ) single color ELISpot kit (Cellular Technology) according to the manufacturer’s protocol. Briefly, 96- well plates were coated with IFN- ⁇ capture antibody overnight at 4°C. The next day, plates were washed with phosphate-buff ered saline (PBS) and splenocytes from immunized mice were plated at 500,000 cells/well with no peptide or 10 ⁇ g/mL GUCY2C 254-262 peptide in 0.1% dimethyl sulfoxide (DMSO) in CTL-TEST medium (Cellular Technology) for 24 hours at 37°C.
  • IFN- ⁇ mouse interferon-y
  • Cellular Technology Cellular Technology
  • splenocytes were plated at 600,000-800,000 cells/well with decreasing concentrations of GUCY2C 254-262 peptide (10 ⁇ g/mL to 56 ⁇ g/mL) normalized to 106 cells/well. After incubation, cells were removed, and development reagents were added to detect IFN- ⁇ -producing spot-forming cells. The number of spot-forming cells per well was determined using the SmartCount and Autogate functions of an ImmunoSpot S6 Universal Analyzer (Cellular Technology). GUCY2C- specific responses were calculated by subtracting mean spot counts of 0.1% DMSO wells from peptide-stimulated wells.
  • GUCY2C-expressing mouse (BALB/c) CT26 colorectal cancer cells were used for in vivo tumor studies. Luciferase-expressing cells were generated by transduction with lentiviral supernatants produced by 293FT cells (Invitrogen) with pLenti4-V5-GW- luciferase. For tumor experiments, BALB/cJ mice were immunized with 1010 vp of Ad5- GUCY2C-S1, Ad5.F35-GUCY2C-S1, or PBS (control) 7 days before delivering 5x10 5 CT26 cells into tail veins.
  • Tumor burden was quantified weekly by subcutaneous injection of 3.75 mg of D-luciferin potassium salt (Gold Biotechnologies) in PBS followed by an 8 min incubation and imaging with a 10 s exposure using a Caliper IVIS Lumina XR imaging station (PerkinElmer). Total radiance (photons/second) was measured using Living Image In Vivo Imaging Software (PerkinElmer).
  • Serum samples were obtained previously from patients before immunization with Ad5-GUCY2C-PADRE (NCT01972737) approved by the Thomas Jefferson University Institutional Review Board. Neutralizing antibody titers against Ad5 and Ad5.F35 vectors were quantified. Briefly, dilutions of heat-inactivated serum samples were added to 96- well tissue culture plates containing 10 5 A549 cells (ATCC) and infected with 10 8 vp of GFP-expressing Ad5 or Ad5.F35 virus (Ad5-CMV-eGFP or Ad5.F35-CMV-eGFP, respectively; Baylor Vector Development Lab).
  • eGFP fluorescence (490 nm excitation, 510 nm emission) was quantified using a POLARstar Optimate plate reader (BMG Labtech). Sample fluorescence was normalized to control wells containing cells and virus (0% neutralization) or wells containing cells alone (100% neutralization). Titers were quantified using non-linear regression as the serum dilution producing 50% neutralization (Prism v8, GraphPad Software).
  • mice were exposed intranasally to 10 10 Ad5-GFP once or twice at a 4-week interval. Thirty days after the last exposure, Ad5 NAbs were quantified in sera as described above and mice were immunized intramuscularly with 10 11 vp of Ad5-GUCY2C-S1 or Ad5.F35-GUCY2C-S1.
  • mice were immunized intramuscularly with a single dose of 10 11 vp of Ad5.F35-GUCY2C-S1, three doses of 10 11 vp of Ad5.F35-GUCY2C-S1 at 28-day intervals, or PBS (control). Animals were monitored for adverse events once daily with additional evaluations on the day of dosing (5 min, 1 hour, and 3 hours after dosing).
  • log-transformed vaccine response magnitude was compared in mice of different genders, cohorts, and treatment regimens for up to three-way interactions, with stepwise backward variable selection by Akaike information criterion using R package MASS.
  • Ad5.F35 chimeric adenovirus
  • Ad5-GUCY2C-S1 is a replication-deficient human Ad5 expressing the mouse GUCY2C extracellular domain fused to the I-Ed-restricted CD4+ epitope known as site 1 at its C-terminus.
  • Ad5.F35-GUCY2C-S1 To generate Ad5.F35-GUCY2C-S1, the Ad5 fiber (L5) was replaced with the Ad35 fiber ( Figure 6 panel B).
  • Replication-deficient Ad5-GUCY2C-S1 and Ad5.F35-GUCY2C-S1 generated in HEK293 cells produced dose- dependent ( Figure 6 panel C) and time-dependent ( Figure 6 panel D) expression of GUCY2C-S1 protein in A549 human alveolar basal epithelial cells in vitro.
  • Ad5.F35-GUCY2C-S1 induces GUCY2C-specific antitumor immunity
  • Ad5 and Ad5.F35 vaccines produced GUCY2C-specific CD8 + T cells of comparable avidity Figure 7 panel C), a critical determinant of the antitumor efficacy of GUCY2C-targeted vaccines.
  • GUCY2C-specific antibody responses have no detectable antitumor activity.
  • Ad5 and Ad5.F35 vaccines produced comparable S1-specific CD4 + T-cell responses ( Figure 7 panel D).
  • Ad5.F35 resists Ad5-directed immunity in mice and humans
  • Ad5.F35-based vaccine resistance to pre- existing Ad5 immunity was quantified in a model of respiratory pre-exposure to Ad5, the natural route of infection in patients, followed by vaccination and quantification of GUCY2C-specific T-cell responses.
  • mice (not pre-exposed to Ad5; naive) and those that were pre-exposed once (lx) or twice (2x) to intranasal Ad5 were vaccinated after 4 weeks with intramuscular Ad5 or Ad5.F35 expressing GUCY2C-S1, and immune responses were quantified 2 weeks later (Figure 9 panel A).
  • one Ad5 pre- exposure induced moderate ( ⁇ l:200) Ad5 NAbs and reduced GUCY2C-specific T-cell responses -75%, while two pre-exposures induced high (>1:200) Ad5 NAbs and reduced GUCY2C-specific T-cell responses >90% following Ad5 vaccination (Figure 9 panel B).
  • NAb titers against Ad5 and Ad5.F35 were quantified using an established Ad5/Ad5.F35 reporter virus inhibition bioassay in serum samples collected prior to vaccination with Ad5-GUCY2C-PADRE.
  • Ad5.F35 -specific NAb titers were substantially lower than Ad5-specific titers ( Figure 9 panel D).
  • Ad5 seroprevalence is >70% across multiple countries, highlighting an unmet need for alternative vectors.
  • Ad5.F35 resists pre-existing Ad5 immunity and induces transgene- specific antitumor immunity. Indeed, Ad5.F35 is less susceptible to neutralization associated with Ad5 exposure in mice and humans and generates a substantially higher proportion of vaccine responders in mice pre-exposed to Ad5.
  • NAb responses are dependent on the route of exposure. Indeed, respiratory infections elicit fiber- specific NAbs while intramuscular exposure induce capsid-specific NAbs. These qualitative differences in NAb responses, reflecting varying routes of immunization, may contribute to observational discrepancies between laboratories.
  • Ad26, Ad35, and Ad48 vectors have been advanced into phase I clinical trials.
  • a comparison of Ad5, Ad26, Ad35, and Ad48 immunity among healthy patients revealed that endemic Ad35 seropositivity was lowest across global populations, reinforcing chimeric strategies employed herein.
  • the first hexon-chimeric adenovirus, comprising Ad5 and Ad48 components was safe and immunogenic in patients.
  • Ad5-Ad35 chimeric vectors more efficiently transduce a variety of human cell types in vitro compared with either parental vector.
  • Ad5 transduction efficiency in vivo may be several-fold higher than Ad5.F35.
  • Ad5 fiber binds to CXADR (coxsackievirus and adenovirus receptor) while the Ad35 fiber binds to CD46, suggesting the two viruses may infect distinct cell types.
  • checkpoint inhibitors While checkpoint inhibitors have generated practice-shifting results in the clinic and defined immunotherapy as an effective strategy for the treatment of several malignancies, they have not been universally successful.
  • the dearth of neoepitopes in many cancer types, including microsatellite stable colorectal and pancreatic (second and third leading causes of cancer mortality, respectively) makes them insensitive to checkpoint blockade.
  • examination of neoepitopes presented on the surface of five colorectal cancer specimens revealed a total of three neoepitopes.
  • vaccines targeting cancer-associated self-antigens have re-emerged, alone and in combination with checkpoint inhibitors, as a strategy to prevent and treat metastases from these cold tumors.
  • Checkpoint inhibitors have become first-line therapy in the metastatic setting for some cancers, while chimeric antigen receptor expressing T cells (CAR-T cells) are being deployed in patients with metastatic and refractory disease.
  • CAR-T cells chimeric antigen receptor expressing T cells
  • few cancer immunotherapies have been developed for early-stage cancer patients with “no evidence of disease” (NED) following conventional surgical/radio/chemotherapies, who are at significant risk of disease recurrence. Indeed, ⁇ 25% of stage II, and ⁇ 50% of stage III, patients with colorectal cancer recur following surgery and chemotherapy, while 70% of patients with resectable pancreatic cancer experience recurrence.
  • Vaccines targeting tumor-associated antigens may provide safe and effective immunotherapies for the secondary prevention of metastatic disease in patients with NED who are otherwise ineligible to receive checkpoint inhibitors or CAR-T cells.
  • Ad5.F35 may be preferable to the widely used Ad5 vector and warrants further investigation. Indeed, they suggest that ongoing clinical investigations of GUCY2C-directed immunotherapy in patients with GUCY2C-expressing cancers, including colorectal, pancreatic, gastric, and esophageal, could benefit from using the Ad5.F35, rather than the Ad5, vector. In that context, an upcoming clinical trial will examine the safety, immunogenicity, and resistance to pre-existing immunity of Ad5.F35-GUCY2C-PADRE in patients with GI cancer (NCT04111172).
  • Lm Recombinant attenuated Listeria monocytogenes
  • APCs antigen-presenting cells
  • Th cells CD4-1- T-helper cells
  • CTLs CD8+ cytotoxic T cells
  • Ad5-GUCY2C-PADRE immunogenicity is limited in human populations by pre-existing neutralizing antibodies (NAbs) targeting the Ad5 viral vector.
  • NAbs neutralizing antibodies
  • GUCY2C-specific immune responses are characterized by the absence of CD4+ T-cell responses, essential for the induction of CD8+ T- and B-cell responses.
  • a Lm vaccine incorporating GIJCY2C should be resistant to vector- specific immunity and, reflecting its tropism for APCs, should induce Lm- specific CD4+ T-cell responses that provide CD4+ T-cell help to GUCY2C-specific CD8-1- T and B ceils, leading to CRC elimination.
  • Lm-LLO -GUCY2C is superior to current GUCY2C vaccines, overcoming neutralizing antibodies and GUCY2C-specific CD4+ T-cell tolerance, to produce safe and effective CRC immunotherapy.
  • This proposal will define the (1) immunogenicity, (2) antitumor activity in a metastatic CRC model, and (3) safety of Lm-LLO-GUCY2C.
  • Lm-LLO-GUCY2C will be produced, and its immunogenicity will be tested in mice by quantifying GUC Y2C-specific immune responses (CD4+ and CD8+ T and B cells). Further, Lm-specific CD4+ T-cell responses will be quantified, and their role in inducing GUCY2C-specific responses will be determined by CD4-depletion studies. The antitumor efficacy of Lm-LLO-GUCY2C will be tested in a mouse model of metastatic CRC and compared to the benchmark GUCY2C vaccine (Ad5-GUCY2C-S1). Finally, Lm-LLOGUCY2C toxicity will be examined, particularly in normal GUCY2C- expressing tissues. Positive and negative controls for the proposed studies include Ad5- GUCY2C-S1. and Lm-LLO (lacks GUCY2C), respectively.
  • CRC Listeria-based cancer vaccine targeting GUCY2C (Lm-LLO-GUCY2C) as a potential CRC immunotherapy.
  • CRC is the fourth most common neoplasm, with ⁇ 150,000 new cases per year, and the second leading cause of cancer mortality, in civilians and the military', with a mortality of ⁇ 50%.
  • the novel recombinant Listeria monocytogenes vaccines are first tested in mouse models of colorectal cancer to determine their activity, efficacy, and safety.
  • Task 1 Generate Lm-LLO-GCC and control Lm vaccines
  • Task 2 Determine the ability of Lm-LLO-GCC to overcome tolerance in WT mice. Quantify Lm-LLO-GCC-induced immune responses in WT and KO mice
  • Task 3 Determine whether GCC-specific responses are CD4+ T-cell dependent
  • Task 5 Compare the impact of vector-specific immunity on immune responses to Lm-LLO-GCC and Ad5-GCC-S1. Quantify immune responses in Lm- LLOGCC or Ad5-GCC-S1 -immunized mice with pre-existing vector specific immunity
  • Task 6 Compare the impact of vector-specific immunity on Lm-LLO-GCC and Ad5-GCC-S1 antitumor efficacy. Quantify antitumor efficacy of Lm-LLOGCC or Ad5-GCC-S1 in mice with pre-existing vector-specific immunity
  • Lm-GCC and control vaccines were quality controlled by confirming GCC expression in supernatants of Lm cultures ( Figure 15).
  • the LLO-GCC or LL0-GCC-S1 fusion proteins were detected in supernatants using anti-GCC or anti-LLO antibodies.
  • LLO-GCC fusion protein expression was confirmed in 2nd generation Lm- LLO-GCC vaccines by western blot. Because each 2nd generation vaccine contains a different GCC fragment, multiple GCC-specific monoclonal antibodies were used to detect GCC-LLO fusion proteins in Lm supernatants ( Figure 18). These data confirm LLO-GCC fusion protein expression by each recombinant Lm vaccine. As expected, the shorter fusion proteins were expressed at higher levels than the full-length LLOGCC product produced in the 1st generation vaccine.
  • mice 2nd generation Lm-LLO-GCC vaccines containing GCC fragments were administered to Gcc-/- ( Figure 19 panel A) or Gcc+/+ ( Figure 19 panel B) mice. Because Gcc-/- mice produce only CD4 + T-cell responses and Gcc+/+ produce only CD8 + T-cell responses, mice received only the vaccine fragments containing those epitopes. Gcc-/- mice produced robust CD4 + T-cell responses against GCC when immunized with the CD4 + T-cell epitope containing fragments 1 and 2 ( Figure 19 panel A).
  • Colorectal cancer is the second leading cause of cancer death and is the fourth most commonly diagnosed cancer in the United States. Moreover, the 5-year survival for patients with metastatic CRC is currently 14% and has remained relatively stagnant for decades, highlighting a lack of effective therapies for preventing and treating metastatic CRC. In this context, the intestinal receptor and tumor associated antigen guanylyl cyclase C (GUCY2C) has emerged as a developing immunotherapeutic option. A recent phase I study in CRC patients demonstrated immunogenicity and safety of an adenovirus-based vaccine against GUCY2C (Ad-GUCY2C) immunogenicity.
  • Ad-GUCY2C adenovirus-based vaccine against GUCY2C
  • Ad5.F35-GUCY2C-S1 and Ad5.F35-GFP vaccines used in this study were produced by the Baylor College of Medicine in the Cell and Gene Therapy Vector Development Lab and certified to be negative for replication-competent adenovirus, mycoplasma, and host cell DNA contamination.
  • Lm-GUCY2C and Lm-LacZ were ordered from ATCC and serves as the parental strain for all Lm vaccines utilized in this study.
  • Recombinant Lm-GUCY2C and Lm-LacZ was generated by synthesizing mouse GUCY2C extracellular domain23-429 or ⁇ -galactosidase 618-1024 respectively in-frame with the first 100 amino acids of ActA protein under control of the actA promoter.
  • the resulting sequence was cloned into the pPL2 integration vector and integrated into the Lm chromosome.
  • Lm strains were grown in brain-heart infusion broth (Fisher Scientific) until OD 600 ⁇ 1, aliquoted, and stored at -80oC. On the day of experiment, aliquots were thawed, incubated at 37°C for 60 minutes, washed 2x in PBS, and diluted to a desired concentration in PBS for vaccination.
  • the mouse macrophage cell line J774A.1 was cultured in DMEM supplemented with 10% fetal bovine serum. J774A.1 cells were infected at a 10:1 multiplicity of infection with Lm-GUCY2C or control Lm. After a 1 h incubation, cells were washed 2x in PBS, resuspended in media containing 10 ⁇ g/mL gentamicin to eliminate free extracellular bacteria and incubated an additional 5 h. For immunofluorescence studies, Lm was labeled prior to infection by incubation with 2mM CellTracker Red CMPTPX dye for 10 minutes at 37°C.
  • GUCY2C protein was stained using the anti-GUCY2C monoclonal antibody MS20 and p60 stained using the anti-p60 monoclonal antibody p6017 (AdipoGen).
  • mice Eight week-old male and female BALB/cJ mice were purchased from the Jackson Laboratory for experiments. Animal protocols were approved by the Thomas Jefferson University Institutional Animal Care and Use Committee (Protocol 01956).
  • mice received 10 10 vp of Ad5.F35-GUCY2C-S1 or Ad5.F35- GFP as a control administered intramuscularly (i.m.) as two 50uL injections, one in each hind limb.
  • Ad5.F35-GUCY2C-S1 or Ad5.F35- GFP as a control administered intramuscularly (i.m.) as two 50uL injections, one in each hind limb.
  • Lm immunizations 5x10 6 colony-forming units (CFU) of Lm-GUCY2C, empty Lm, or Lm-LacZ were administered intravenously (i.v.) as a 100uL suspension in PBS.
  • CFU colony-forming units
  • Ad5 immunity was induced in BALB/cJ mice by intranasal exposure to 10 10 Ad5- GFP. Twenty-eight days after infection, mice were bled, sera collected and immunized with 10 11 vp of Ad5.F35-GUCY2C-S1 followed by 5x10 6 CFU of Lm-GUCY2C or control Lm 21 d later. Ad5 neutralizing antibody titers in mice were quantified as previously described. IFN- ⁇ ELISpot assay
  • ELISpot assays were performed using a mouse interferon-y (IFN- ⁇ ) single color ELISpot kit (Cellular Technology Limited) according to the manufacturer’s protocol. Briefly, 96- well plates were coated with IFN- ⁇ capture antibody at 4°C. After an overnight incubation, plates were washed with PBS and splenocytes from immunized mice plated in a 0.1% DMSO solution in CTL-TEST medium (Cellular Technology Limited) with or without 10 ⁇ g/mL GUCY2C 254-262 peptide and incubated at 37°C for 24 hours.
  • IFN- ⁇ mouse interferon-y
  • splenocytes were plated with various concentrations of GUCY2C 254-262 peptide (10 ⁇ g /mL to 3pg/mL. The next day, cells were removed and development reagents were added to detect IFN- ⁇ -producing spot-forming cells. The number of spot- forming cells per well was calculated using the SmartCount and Autogate functions of an ImmunoSpot S6 Universal Analyzer (Cellular Technology Limited). GUCY2C-specific responses were calculated by subtracting mean spots counts of 0.1% DMSO wells from peptide-pulsed wells.
  • Intracellular cytokine staining 10 6 splenocytes from immunized mice were plated in a 96-well plate in the presence of DMSO or 10ug/mL GUCY2C 254-262 peptide and anti-CD107-FITC (clone 1D4B). Cells were incubated at 37°C for Ih, protein transport inhibitor cocktail (eBioscience) was added and splenocytes were incubated an additional 5 hours at 37°C . Cells were stained with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen), anti- CD 8PerCP-Cy 5.5 (53-6.7; BD Biosciences), anti-CD19-BV510 (6D5; Biolegend).
  • BD Cytofix/Cytoperm Kit (BD Biosciences) was used to permeabilize and intracellular cytokines stained using anti IFN- ⁇ (XMG1.2; BD Biosciences) and anti-MIP1 ⁇ -APC (39624; R&D Systems). Cells were fixed in 4% paraformaldehyde and analyzed on a BD LSR II flow cytometer. Analyses were performed using FlowJo software (TreeStar).
  • a GUCY2C and luciferase-expressing mouse (BALB/c) CT26 colorectal cancer cell line was generated as described previously and used for in vivo tumor studies.
  • mice received 5x10 5 CT26 cells via intravenous tail vein.
  • Tumor burden was quantified weekly by subcutaneous injection of a 3.75mg of D- luciferin potassium salt (Gold Biotechnologies) in PBS followed by an eight-minute incubation and imaged after ten-second exposure using a Caliper IVIS Lumina XR imaging station (PerkinElmer). Total radiance (photons/second) was measured using Living Image In Vivo Imaging Software (PerkinElmer).
  • mouse GUCY2C 23-429 was codon optimized for Listeria monocytogenes using Java Codon Adaptation Tool and synthesized downstream of actA promoter, ActAN100, and an enhancer sequence as depicted in Figure 24 panel A.
  • the resulting sequence was cloned into the pPL2 integration vector and stably integrated into the genome of the live attenuated double-deleted strain Lm ⁇ actA ⁇ inIB.
  • the J774A.1 macrophage cell line was infected with Lm-GUCY2C or control Lm strain. Following a 6 hour incubation, macrophages were stained for GUCY2C protein expression by western blot ( Figure 24 panel B) and immunofluorescence ( Figure 24 panel C).
  • GUCY2C immunogenicity and antitumor immunity were evaluated utilizing a prime-boost strategy in which Lm-GUCY2C and Ad5.F35-GUCY2C-S1 vaccines were administered 21 days apart as homologous or heterologous vaccinations.
  • the heterologous immunization regimen utilizing Ad5.F35-GUCY2C-S1 to ‘prime’ GUCY2C immune responses followed by Lm-GUCY2C to ‘boost’ generated significantly higher GUCY2C-specific CD8 + T cell responses as quantified by IFN- ⁇ ELISpot compared to all other immunization regimens (Figure 25 panel A).
  • Ad5.F35-GUCY2C-S1 + Lm-GUCY2C immunization significantly reduced metastatic tumor burden (Figure 25 panel B and C), and increased median survival (Figure 25 panel D) compared to other methods of vaccination.
  • the order of immunization was essential for optimal GUCY2C immunity, with Ad5.F35-GUCY2C-S1 + Lm-GUCY2C inducing a >15-fold increase in GUCY2C-specific CD8 + T-cells (p ⁇ 0.0001) and significantly improving median survival (71 d vs.
  • a known limitation of viral-based vaccines is the ability for vector- specific immunity to interfere with the immunogenicity of the target vaccine antigen.
  • neutralizing antibodies (NAbs) against the common adenovirus serotype 5 (Ad5) are detectable in >70% of healthy donors and have been demonstrated to blunt the efficacy of adenovirus-based vaccines.
  • Ad5.F35 chimeric adenoviruses, such as Ad5.F35, are less susceptible to neutralization associated with Ad5 NAbs, the effect is modest and thus GUCY2C-specific immune responses of Ad5.F35-GUCY2C-S1 are partially reduced in the presence of prior Ad5 exposure.
  • mice were exposed intranasally to 10 10 vp of Ad5-GFP or PBS twenty-eight days prior to the start of a Ad5.F35-GUCY2C-S1 + Lm-GUCY2C vaccination regimen.
  • Ad5-GFP exposure induced NAbs in mice at the time of vaccination ( Figure 26 panel B).
  • Lm-GUCY2C boosted GUCY2C-specific CD8 + T cell responses in naive mice and mice pre-exposed to Ad5-GFP ( Figure 26 panel C).
  • Lm-GUCY2C vaccination of naive and Ad5-GFP exposed mice similarly enhanced antitumor immunity as quantified by a reduced metastatic tumor burden ( Figure 26 panel D) and extended median survival ( Figure 26 panel E).
  • Lm-GUCY2C may be effective at boosting GUCY2C-specific immunity in circumstances associated with a poor GUCY2C priming vaccination.
  • mice immunized with decreasing concentrations of GUCY2C 254-262 peptide were pulsed and quantified the IFN- ⁇ response.
  • the EC50 of mice immunized with prime-boost was shifted ⁇ 2.5-fold (0.0046 ⁇ g/mL vs. 00 l 8 ⁇ g/mL, p ⁇ 0.0001), suggesting an enrichment of high avidity GUCY2C-specific T cells in mice following prime-boost (Figure 27 panel A).
  • mice were immunized with 10 10 vp Ad5.F35-GUCY2C-S1 on day 0, followed by two additional immunizations of 5x10 6 CFU Lm-GUCY2C on day 21 and day 42. Seven and thirty days following final immunization, mice were sacrificed and organs harvested for assessment of acute and/or chronic toxicity respectively. An additional cohort received PBS on all immunization days. No signs of toxicity in acute or chronic cohorts were observed during in-life observations or survival (Figure 28 panel B). Notably, male but not female mice in acute and chronic cohorts had decreased body weights throughout the study compared to the control cohort ( Figure 28 panel C and D).
  • mice in the acute and/or chronic cohorts exhibited decreased stomach weights.
  • mice in the acute cohort most recently immunized with Lm-GUCY2C exhibited splenomegaly, consistent with prior studies and likely due to Lm tropism for the spleen.
  • Adenovirus-based cancer vaccines have in part been hindered by the high proportion of individuals with Ad5 -specific NAbs that block reinfection and therefore limit vaccine efficacy upon immunization. While the use of rare serotype and chimeric adenoviral vectors, such as Ad5.F35, are less susceptible to neutralization associated with Ad5 pre-existing immunity, the induction of vector- specific NAbs upon vaccination limit the utility of additional immunizations. Thus, heterologous immunizations utilizing two different vectors may be preferable to homologous immunization in this setting. Moreover, in contrast to viral vectors, bacterial vectors such as Lm do not induce NAbs upon vaccination. Thus, as GUCY2C immunity wanes over time, repeated vaccinations with Lm-GUCY2C are permissible and may be necessary in patients to consistently elevate GUCY2C immunity to therapeutic levels.
  • Lm-GUCY2C induced potent expansion of memory GUCY2C-speicfic CD8 + T cell cells following Ad5.F35-GUCY2C-S1 priming
  • Lm-GUCY2C alone was poorly effective as a single-agent therapy.
  • homologous Lm-GUCY2C vaccination generated a notable absence of GUCY2C-specific CD8 + T cells by ELISpot and conferred no protection against CRC challenge.
  • studies exploring Lm vaccines as single-agent therapies have reported mixed success.
  • Lm vaccines against the tumor antigens HER2 and PSA generate potent antitumor immunity as monotherapies while Lm vaccines against other tumor antigens including PAP and mesothelin similarly demonstrated limited immunogenicity alone and were utilized as heterologous prime-boost immunizations. Additionally, enhanced antitumor immunity combining Lm vaccines with immune modulators such as anti-GITR and anti-PD-1 antibodies have been reported. Thus, additional investigation into understanding why Lm-GUCY2C does not prime detectable GUCY2C immune responses alone and pairing immune modulators with Lm- GUCY2C may yield important insights into Lm-GUCY2C biology and lead to further enhancements in GUCY2C immunity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des compositions comprenant un adénovirus modifié AD5.F35 qui comprend une séquence codante de séquences de domaine extracellulaire GUCY2C solubles. L'invention concerne également des compositions comprenant un vecteur de Listeria monocytogenes incluant la séquence codante des séquences du domaine extracellulaire de GUCY2C soluble. L'invention concerne également des méthodes de traitement des individus diagnostiqués avec un cancer/tumeur exprimant GUCY2C et des méthodes de prévention des micro-métastases.
PCT/US2020/059752 2019-11-07 2020-11-09 Vaccins anti-gucy2c et vaccination WO2022098372A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2022526700A JP2023548255A (ja) 2019-11-07 2020-11-09 抗ｇｕｃｙ２ｃワクチンとワクチン接種
KR1020227019215A KR20230026980A (ko) 2019-11-07 2020-11-09 항-gucy2c 백신 및 백신접종
EP20960974.2A EP4055176A4 (fr) 2020-11-07 2020-11-09 Vaccins anti-gucy2c et vaccination
AU2020475819A AU2020475819A1 (en) 2019-11-07 2020-11-09 Anti-GUCY2C vaccines and vaccination
CA3158649A CA3158649A1 (en) 2019-11-07 2020-11-09 Anti-gucy2c vaccines and vaccination

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62/932,499 2019-11-07
US62/933,361 2019-11-08
US202062932499P 2020-11-07 2020-11-07
US202062933361P 2020-11-08 2020-11-08

Publications (1)

Publication Number Publication Date
WO2022098372A1 true WO2022098372A1 (fr) 2022-05-12

Family

ID=81458164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/059752 WO2022098372A1 (fr) 2019-11-07 2020-11-09 Vaccins anti-gucy2c et vaccination

Country Status (3)

Country Link
EP (1) EP4055176A4 (fr)
AU (1) AU2020475819A1 (fr)
WO (1) WO2022098372A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050242A1 (fr) * 2009-10-23 2011-04-28 Millennium Pharmaceuticals, Inc. Molécules d'anticorps anti-gcc, compositions et procédés apparentés

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050242A1 (fr) * 2009-10-23 2011-04-28 Millennium Pharmaceuticals, Inc. Molécules d'anticorps anti-gcc, compositions et procédés apparentés

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ADAM E. SNOOK; MICHAEL S. MAGEE; SCOTT A. WALDMAN: "GUCY2C-targeted cancer immunotherapy: past, present and future", IMMUNOLOGIC RESEARCH, HUMANA PRESS INC, NEW YORK, vol. 51, no. 2 - 3, 30 October 2011 (2011-10-30), New York , pages 161 - 169, XP019990822, ISSN: 1559-0755, DOI: 10.1007/s12026-011-8253-7 *
FLICKINGER JR JOHN C, SINGH JAGMOHAN, CARLSON ROBERT, LEONG ELINOR, BAYBUTT TREVOR R, BARTON JOSHUA, CAPAROSA ELLEN, PATTISON AMAN: "Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 8, no. 2, 20 August 2020 (2020-08-20), pages e001046, XP055939176, DOI: 10.1136/jitc-2020-001046 *
See also references of EP4055176A4 *
SNOOK ADAM E., BAYBUTT TREVOR R., XIANG BO, ABRAHAM TARA S., FLICKINGER JOHN C., HYSLOP TERRY, ZHAN TINGTING, KRAFT WALTER K., SAT: "Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, no. 1, 1 December 2019 (2019-12-01), pages 1 - 12, XP055939172, DOI: 10.1186/s40425-019-0576-2 *
SNOOK ADAM: "Metastatic Colorectal Cancer Immunotherapy with GUCY2C-Expressing Listeria monocytogenes", PROJECT REPORT, 1 September 2018 (2018-09-01), pages 45pp, XP055939177, Retrieved from the Internet <URL:https://apps.dtic.mil/sti/citations/AD1062516> [retrieved on 20220706] *

Also Published As

Publication number Publication date
AU2020475819A1 (en) 2022-06-23
EP4055176A4 (fr) 2024-04-17
EP4055176A1 (fr) 2022-09-14

Similar Documents

Publication Publication Date Title
US10563224B2 (en) Replication defective adenovirus vector in vaccination
EP1998804B1 (fr) Compositions comprenant un adénovirus recombiné et un adjuvant
ES2795833T3 (es) Composiciones para la vacunación contra el virus del Ebola
JP2019123734A (ja) 免疫応答の増進を目的とする方法及び組成物
CN107454848B (zh) 用于诱导针对丝状病毒感染的保护性免疫的方法和组合物
KR20180056782A (ko) 재조합 리스테리아 백신 균주 및 암 면역요법에서 이를 이용하는 방법
US11883487B2 (en) Vaccine for use in the prophylaxis and/or treatment of a disease
AU2021236141B2 (en) Treatment of covid-19 and methods therefor
Neukirch et al. Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice
EP3941513A1 (fr) Procédés pour induire une réponse immunitaire contre des néoantigènes
WO2022098372A1 (fr) Vaccins anti-gucy2c et vaccination
CA3158649A1 (en) Anti-gucy2c vaccines and vaccination
US20230059344A1 (en) Medical Uses of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA)
US11857620B2 (en) Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
WO2022084663A1 (fr) Compositions et métodes permettant d&#39;induire une réponse immunitaire
EP4118210A1 (fr) Traitement du covid-19 et procédés correspondants
Sas HER-2/neu-targeted immunoprevention of breast cancer
AU2010226945A1 (en) Vaccination regimen

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3158649

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022526700

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20960974

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020475819

Country of ref document: AU

Date of ref document: 20201109

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020960974

Country of ref document: EP

Effective date: 20220607

NENP Non-entry into the national phase

Ref country code: DE